denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Aakko, S.
Aalbers, A.
584 - Single Center Experience with Off-Label Benralizumab in Refractory Hypereosinophilic Syndrome Demonstrates a Satisfactory Safety and Efficacy Profile
2401 - A New Genetic Immunodeficiency Syndrome Caused By Autosomal Dominant Mutations in LCP1 Identified By Mosaic Tetraploidy and Severe Neutropenia in Unrelated Pedigrees
2401 - A New Genetic Immunodeficiency Syndrome Caused By Autosomal Dominant Mutations in LCP1 Identified By Mosaic Tetraploidy and Severe Neutropenia in Unrelated Pedigrees
Aardalen, K.
1363 - PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
4478 - Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation
4478 - Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation
Aarup, K.
Aasen Gausman, J.
Ababneh, O.
Abad, C.
Abada, P. B.
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Abadi, U.
Abagyan, R.
Abáigar, M.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
Abajas, Y. L.
Abarah, W.
Abate, A.
Abaza, Y.
599 - Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
2656 - Synthetic Lipid Nanoparticles Actively Target Acute Myeloid Leukemia (AML) Cells and Induce Ferroptosis through Decreased Expression of Glutathione Peroxidase 4
2699 - Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
2795 - Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
3051 - Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies
4022 - Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)
4072 - Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4076 - Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
2656 - Synthetic Lipid Nanoparticles Actively Target Acute Myeloid Leukemia (AML) Cells and Induce Ferroptosis through Decreased Expression of Glutathione Peroxidase 4
2699 - Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
2795 - Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
3051 - Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies
4022 - Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)
4072 - Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4076 - Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part
Abbadi, S.
Abbas, A.
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
Abbas, H. A.
61 - Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
596 - Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
1384 - Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)
2125 - Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
2814 - Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
596 - Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
1384 - Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)
2125 - Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
2814 - Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes
Abbas, K.
Abbas, T.
Abbattista, M.
Abbondanza, D.
Abbott, D.
958 - Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas
1421 - Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study
2751 - Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza
2753 - Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia
4129 - Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia
1421 - Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study
2751 - Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza
2753 - Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia
4129 - Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia
Abbott, J. J.
Abbott, N.
Abboud, Sr., C.
Abboud, R.
Abdalla, A.
Abdallah, A. O.
757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
2211 - Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
3246 - Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4562 - Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
2211 - Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
3246 - Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4562 - Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
Abdallah, M.
Abdallah, N.
Abdel Rahman, Z.
Abdel-Azim, H.
Abdel-Qadir, H.
Abdel-Wahab, O.
201 - Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia
306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
456 - RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients
480 - Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
934 - Systematic Evaluation of AML-Associated Antigens Identifies Novel Anti-U5 snRNP200 Therapeutic Antibodies for the Treatment of AML
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
2540 - Chronic Inflammation Drives p53 Mutant Clonal Hematopoiesis Via Activating the NLRP1 Inflammasome
3063 - Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
4583 - Immune Escape after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia
306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
456 - RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients
480 - Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
934 - Systematic Evaluation of AML-Associated Antigens Identifies Novel Anti-U5 snRNP200 Therapeutic Antibodies for the Treatment of AML
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
2540 - Chronic Inflammation Drives p53 Mutant Clonal Hematopoiesis Via Activating the NLRP1 Inflammasome
3063 - Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
4583 - Immune Escape after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia
Abdelaziz, E. M.
Abdelbaset-Ismail, A.
822 - Novel Evidence That Intracellular Complement Network (complosome) Is Expressed in Hematopoietic Stem Cells (HSPCs) and Regulates Their Trafficking, Metabolism, and Proliferation in an Intracrine-Dependent Manner By Engaging Pattern Recognition Receptor Nlrp3 Inflammasome
1209 - Novel Evidence That Pineal Gland Hormone Melatonin Inhibits Migration of Hematopoietic Stem/Progenitor Cells (HSPCs) By Inhibiting Nlrp3 Inflammasome and Upregulating Heme Oxygenase-1 (HO-1) - Implications to Understand Better Diurnal Trafficking of HSPCs and Anti-Inflammatory Effects of Melatonin
1947 - Novel Observation That Trafficking of Hematopoietic Stem Progenitor Cells (HSPCs) Involves Activation of Nlrp3 Inflammasome That Provides Cholesterol and Sphingolipids for the Formation of Lipid Rafts on the Outer Cell Membrane That Are Crucial for Proper Responsiveness of HSPCs to Chemoattractant and Hematopoietic Cytokines/Growth Factors
1209 - Novel Evidence That Pineal Gland Hormone Melatonin Inhibits Migration of Hematopoietic Stem/Progenitor Cells (HSPCs) By Inhibiting Nlrp3 Inflammasome and Upregulating Heme Oxygenase-1 (HO-1) - Implications to Understand Better Diurnal Trafficking of HSPCs and Anti-Inflammatory Effects of Melatonin
1947 - Novel Observation That Trafficking of Hematopoietic Stem Progenitor Cells (HSPCs) Involves Activation of Nlrp3 Inflammasome That Provides Cholesterol and Sphingolipids for the Formation of Lipid Rafts on the Outer Cell Membrane That Are Crucial for Proper Responsiveness of HSPCs to Chemoattractant and Hematopoietic Cytokines/Growth Factors
Abdelhakim, H.
Abdelhamed, S.
1272 - Histone Acetyltransferases Are Critical Interacting Proteins in NUP98-Rearranged Acute Myeloid Leukemia
2587 - Human Models of NUP98-Rearranged Leukemia Reveal Fusion-Specific Molecular Mechanisms
2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7
3282 - Establishing Immunocompetent Leukemia Models to Investigate the Impact of CAR T Cells on the Immune Microenvironment and Bone Marrow Niche
3930 - UBTF-TD Expression Is Necessary and Sufficient for Myeloid Cell Expansion
- In Vivo Expression of Samd9l Mutation Impairs Hematopoiesis to Induce Bone Marrow Failure
- Q&A
2587 - Human Models of NUP98-Rearranged Leukemia Reveal Fusion-Specific Molecular Mechanisms
2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7
3282 - Establishing Immunocompetent Leukemia Models to Investigate the Impact of CAR T Cells on the Immune Microenvironment and Bone Marrow Niche
3930 - UBTF-TD Expression Is Necessary and Sufficient for Myeloid Cell Expansion
- In Vivo Expression of Samd9l Mutation Impairs Hematopoiesis to Induce Bone Marrow Failure
- Q&A
Abdelhamid, A. M.
Abdelhay, A.
Abdelkader, B.
Abdelmagid, M.
Abdelmalek, M.
Abdollahi, S.
Abdul Hamid, M.
Abdul-Kadir, R.
Abdulazeez, M.
Abdulhaq, H.
1543 - Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity
2115 - Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis
2115 - Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis
Abdulla, F.
Abdulla, M. A.
Abdullah, M.
Abdulmalik, O. Y.
121 - Lnp-Targeting Hematopoietic Stem Cells and Lentiviral Gene Transfer to Generate and Rescue a Novel Mouse Model of Lethal Alpha-Thalassemia
802 - Examining the Role of Individual Baf Chromatin Remodeling Complex Components in Globin Gene Regulation
1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)
2360 - Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy
2361 - Mechanisms of Polycomb Group Protein-Mediated Fetal Hemoglobin Silencing
4589 - Late-Gestation Hematopoietic Cell Transplantation with Transient T Cell Depletion Significantly Improves Disease Phenotype in the Townes Mouse Model of Sickle Cell Disease
802 - Examining the Role of Individual Baf Chromatin Remodeling Complex Components in Globin Gene Regulation
1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)
2360 - Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy
2361 - Mechanisms of Polycomb Group Protein-Mediated Fetal Hemoglobin Silencing
4589 - Late-Gestation Hematopoietic Cell Transplantation with Transient T Cell Depletion Significantly Improves Disease Phenotype in the Townes Mouse Model of Sickle Cell Disease
Abdulrehman, J.
Abe, K.
Abe, K.
Abe, K.
Abe, Y.
Abedi, M.
265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2140 - Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)
3205 - Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2140 - Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)
3205 - Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
Abedin, S.
65 - Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
4951 - Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)
4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
4951 - Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)
4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
Abedpour, N.
Abel, G. A.
381 - Access and Treatment Equity across the Comprehensive Cancer Center Catchment Area: Targets for Disparities Remediation in Acute Leukemia Research Participation
880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial
2547 - Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics
3550 - Perspectives of Older Patients with Blood Cancers, Caregivers, and Oncology Clinicians on Benefits and Barriers of Technology for Home Functional Assessment
3610 - Anxiety and Depression Among Patients Newly Diagnosed with Lymphoma and Myeloma
880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial
2547 - Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics
3550 - Perspectives of Older Patients with Blood Cancers, Caregivers, and Oncology Clinicians on Benefits and Barriers of Technology for Home Functional Assessment
3610 - Anxiety and Depression Among Patients Newly Diagnosed with Lymphoma and Myeloma
Abel, L.
Abelowitz, N.
Abelson, S.
334 - Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia
3015 - The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
3019 - Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure
3015 - The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
3019 - Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure
Abenhaim, H.
Abenojar, E.
Abernathy, K. M.
Abeykoon, J. P.
13 - High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group
18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
1738 - Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
2334 - Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia
3720 - An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4374 - Efficacy of MEK Inhibitors in Erdheim Chester Disease
18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
1738 - Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
2334 - Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia
3720 - An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4374 - Efficacy of MEK Inhibitors in Erdheim Chester Disease
Abhyankar, S. H.
3323 - Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial
4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
Abid, M. B.
Abidi, M. H.
Abildgaard, N.
556 - Is It Possible to Omit Bone Marrow Biopsy in Diagnostic Workup in Patients with Newly Diagnosed Primary CNS Lymphoma? a Retrospective Analysis in the PET/CT Era
2109 - Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT
3768 - Use of Psychotropic Prescription Drugs and Mental Health in Adult Patients with Primary Immune Thrombocytopenia – a Danish Nationwide Cohort Study
4493 - Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure
2109 - Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT
3768 - Use of Psychotropic Prescription Drugs and Mental Health in Adult Patients with Primary Immune Thrombocytopenia – a Danish Nationwide Cohort Study
4493 - Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure
Abkowitz, J. L.
285 - The Molecular Pathophysiology of Ineffective Erythropoiesis at Single Cell Resolution
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
Abla, O.
Aboagye, E.
Abodunrin, F. O.
Abonour, R.
242 - Single Cell Multiomic Analysis Reveals Relapsed and Refractory Multiple Myeloma Cells Associated with 1q, TP53, and PHF19 alterations That Affect Subclonal Chromatin Accessibility
757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
2004 - Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
3612 - Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
4453 - The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
4479 - Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma
757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
2004 - Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
3612 - Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
4453 - The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
4479 - Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma
Abou Alaiwi, S.
Abou Baker, N.
Abou Mourad, Y.
Abou Mourad, Y.
Abou Zahr, A.
Abouchahla, W.
Aboud, E.
Aboukameel, A.
Abouladze, M.
Abousaud, A.
Abowali, H.
Abraham, A.
1157 - Health-Related Quality of Life in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study
1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
2069 - A Model-Informed Precision Busulfan Dosing in Pediatric Patients Undergoing Hematopoietic Cell Transplantation- Real-World Data
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
2976 - Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
4020 - Intracranial Bleeding in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide-Based Regimens: Impact on Relapse and Survival
4698 - Population Pharmacokinetics of Mycophenolic Acid in Haploidentical Transplant Recipients Receiving Post-Transplant Cyclophosphamide Based GvHD Prophylaxis
1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
2069 - A Model-Informed Precision Busulfan Dosing in Pediatric Patients Undergoing Hematopoietic Cell Transplantation- Real-World Data
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
2976 - Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
4020 - Intracranial Bleeding in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide-Based Regimens: Impact on Relapse and Survival
4698 - Population Pharmacokinetics of Mycophenolic Acid in Haploidentical Transplant Recipients Receiving Post-Transplant Cyclophosphamide Based GvHD Prophylaxis
Abraham, A.
Abraham, A.
Abraham, D. M.
Abraham, G. M.
Abraham, I.
889 - Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
3600 - Racial/Ethnic, Sex, and Income Disparities in Overall Survival (OS) in Chronic Lymphocytic Leukemia (CLL) Patients in the Era of Targeted Therapy: Surveillance, Epidemiology, and End Results (SEER) Registry Analysis (2009-2019)
3600 - Racial/Ethnic, Sex, and Income Disparities in Overall Survival (OS) in Chronic Lymphocytic Leukemia (CLL) Patients in the Era of Targeted Therapy: Surveillance, Epidemiology, and End Results (SEER) Registry Analysis (2009-2019)
Abraham, I.
Abraham, J.
Abraham, K.
Abraham, R. S.
Abraham, S.
Abrahao, R.
3414 - Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
3421 - Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
4520 - Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California
3421 - Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
4520 - Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California
Abramovitz, L.
Abrams, C. S.
Abrams, S.
Abramson, J. S.
655 - Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
2031 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
2031 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
Abramson, Z.
Abreu, M.
Abreu, R. M.
Abrisqueta Costa, P.
951 - A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update
2937 - L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
4208 - Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo
2937 - L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
4208 - Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo
Abrisqueta, P.
443 - Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
1103 - Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic
4205 - Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)
4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
4211 - Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
1103 - Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic
4205 - Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)
4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
4211 - Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
Abrisqueta, P.
155 - Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
320 - Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)
1643 - PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma
4175 - Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications
4202 - Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL‑112)
320 - Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)
1643 - PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma
4175 - Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications
4202 - Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL‑112)
Abro, C.
2259 - Inpatient Burden and Clinical Outcomes of Febrile Neutropenia in Cancer Patients: A National Inpatient Sample Database Analysis
3604 - Impact of Sociodemographic and Socioeconomic Factors on Diffuse Large B-Cell Lymphoma (DLBCL)-Specific Mortality in the United States – a SEER PLUS Database Analysis Spanning 20 Years
3606 - Association of Socioeconomic and Sociodemographic Determinants on Mortality in Hodgkin’s Lymphoma in United States: A 20 Year SEER PLUS Retrospective Analysis
3604 - Impact of Sociodemographic and Socioeconomic Factors on Diffuse Large B-Cell Lymphoma (DLBCL)-Specific Mortality in the United States – a SEER PLUS Database Analysis Spanning 20 Years
3606 - Association of Socioeconomic and Sociodemographic Determinants on Mortality in Hodgkin’s Lymphoma in United States: A 20 Year SEER PLUS Retrospective Analysis
Abro, E. U.
606 - A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
1933 - A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
1933 - A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
Abruzzese, E.
621 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
995 - Domiciliary Nursing Management for Patients Affected By Multiple Myeloma during Covid-19 Pandemia in the Viterbo Home Care Unit: Data Analysis from March 2020 to March 2022
2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
3625 - Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
4326 - Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
4356 - Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
995 - Domiciliary Nursing Management for Patients Affected By Multiple Myeloma during Covid-19 Pandemia in the Viterbo Home Care Unit: Data Analysis from March 2020 to March 2022
2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
3625 - Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
4326 - Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
4356 - Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
Absar, N.
Abu Omar, Y.
Abu Za'nouneh, F. J.
Abu Zaid, M. I.
242 - Single Cell Multiomic Analysis Reveals Relapsed and Refractory Multiple Myeloma Cells Associated with 1q, TP53, and PHF19 alterations That Affect Subclonal Chromatin Accessibility
3826 - Emerging Thrombotic Complications in Patients Undergoing Chimeric Antigen Receptor T Cell Therapies
4453 - The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
4479 - Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma
3826 - Emerging Thrombotic Complications in Patients Undergoing Chimeric Antigen Receptor T Cell Therapies
4453 - The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
4479 - Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma
Abu-Hashyeh, A.
Abu-Samra, M.
Abu-Zeinah, G.
1723 - Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV
1737 - Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis
1740 - Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis
3003 - JAK2V617F Impairs T Cell Differentiation in Polycythemia Vera
3034 - Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival
1737 - Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis
1740 - Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis
3003 - JAK2V617F Impairs T Cell Differentiation in Polycythemia Vera
3034 - Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival
Abuasab, T.
1441 - Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
4038 - The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
4038 - The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
Abubeker, A.
Abujarour, R.
Abujarour, R.
Acampora, D.
1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
Acar, M.
Accomando, B.
Accorsi Buttini, E.
Acenas, D. D.
Acera Gómez, M.
Acha, P.
Acharya, S.
Achebe, M. O. O.
Achenbach, S. J.
Ackbarali, T.
Ackermann, U.
Acosta Medina, A. A.
13 - High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group
1738 - Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
4374 - Efficacy of MEK Inhibitors in Erdheim Chester Disease
1738 - Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
4374 - Efficacy of MEK Inhibitors in Erdheim Chester Disease
Acquazzino, M. A.
Acs, K.
Acuña, P.
1113 - Predictive Value of Platelet Sequestration Studies in Splenectomy Response
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
Acuña-Cruz, E.
Adachi, S.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
Adada, M. M.
Adamia, S.
Adamiak, K.
Adamiak, M.
822 - Novel Evidence That Intracellular Complement Network (complosome) Is Expressed in Hematopoietic Stem Cells (HSPCs) and Regulates Their Trafficking, Metabolism, and Proliferation in an Intracrine-Dependent Manner By Engaging Pattern Recognition Receptor Nlrp3 Inflammasome
3367 - Novel Evidence That the P2X1 Purinergic Receptor – Nlrp3 Inflammasome Axis Orchestrates Optimal Trafficking of Hematopoietic Stem Progenitors Cells (HSPCs)
3367 - Novel Evidence That the P2X1 Purinergic Receptor – Nlrp3 Inflammasome Axis Orchestrates Optimal Trafficking of Hematopoietic Stem Progenitors Cells (HSPCs)
Adams, C. M.
Adams, G.
Adams, J. J.
Adams, J. Y.
Adams, L.
Adams, R.
Adams, R. M.
Adams, R.
Adams, R. J.
Adams, S.
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
2001 - Tvt CAR7: Phase 1 Clinical Trial of Base-Edited “Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL
2001 - Tvt CAR7: Phase 1 Clinical Trial of Base-Edited “Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL
Adamski, A.
Adang, A. E.
Addada, J.
Adejobi, E.
Adekola, K.
Adeli, M.
Adelman, K.
Adema, V.
Ademokun, C.
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2447 - Cognitive Impairment in Patients with Immune Thrombocytopenia
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
2447 - Cognitive Impairment in Patients with Immune Thrombocytopenia
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
Adeoye, O.
Ades, L.
88 - DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation
464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1775 - Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies
3100 - Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1775 - Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies
3100 - Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Adesina, O. O.
Adeyemo, A. A.
Adhikari, S.
Adib, E.
Adili, R.
688 - Elevated Levels of Low Density Lipoprotein (LDL) Trigger VWF Self-Association into Fibers and Bundles and Potentiate Microvascular Thrombosis
3775 - Novel Snake Venom Derived Hemocoagulase Reverses Anticoagulant Effect of Factor Xa Inhibitors, Restores Hemostatic Clot Formation, and Limits Bleeding in Vitro and In Vivo
3775 - Novel Snake Venom Derived Hemocoagulase Reverses Anticoagulant Effect of Factor Xa Inhibitors, Restores Hemostatic Clot Formation, and Limits Bleeding in Vitro and In Vivo
Adintori, P. A.
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
Aditi, S.
Adjallé, R.
Adjei, A. A.
Adlowitz, D. G.
Adra, S.
Adriaanse, F. R.
Adrianzen Herrera, D.
Advani, A.
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
279 - Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry
1746 - ANKRD26 Coding Variants in Myeloid Neoplasia
3062 - Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association
279 - Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry
1746 - ANKRD26 Coding Variants in Myeloid Neoplasia
3062 - Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association
Advani, P.
Advani, R. H.
442 - Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
613 - Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
731 - Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
1618 - Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2872 - Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
613 - Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
731 - Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
1618 - Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2872 - Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
Adzraku, S. Y.
Affer, M.
Affer, M.
Afinowi-Luitz, R.
Afkhami, M.
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
Afolabi, B.
Afonso, M.
3559 - Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study
3565 - Fitusiran Reaches People’s with Hemophilia and Their Caregivers’ Treatment Expectations: Qualitative Semi-Structured Interviews of Participants of ATLAS-OLE Trial (Interim analysis)
3565 - Fitusiran Reaches People’s with Hemophilia and Their Caregivers’ Treatment Expectations: Qualitative Semi-Structured Interviews of Participants of ATLAS-OLE Trial (Interim analysis)
Afrasiabi, A.
Afrin, N.
Afrough, A.
252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
Afshar-Kharghan, V.
Afsharinejad, A.
Aftandilian, C.
2040 - Plasma Microbial Cell-Free DNA to Characterize Infection Vs Cytokine Release Syndrome in Pediatric Patients with B ALL after CAR T Cell Therapy
4009 - Premedication and Therapeutic Drug Monitoring (TDM) for Pegaspargase: A Prospective Multicenter Multi-Ethnic Study of Pediatric and Adolescent Patients
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia
4009 - Premedication and Therapeutic Drug Monitoring (TDM) for Pegaspargase: A Prospective Multicenter Multi-Ethnic Study of Pediatric and Adolescent Patients
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia
Afzali-Hashemi, L.
676 - The Effect of Hematopoietic Stem Cell Transplantation on Cerebral Perfusion and Oxygen Metabolism in Patients with Sickle Cell Disease
1057 - Effect of Voxelotor on Cerebral Perfusion and Cerebral Oxygen Metabolism in Adult Patients with Sickle Cell Disease; Preliminary Results of the Coverage Study
1057 - Effect of Voxelotor on Cerebral Perfusion and Cerebral Oxygen Metabolism in Adult Patients with Sickle Cell Disease; Preliminary Results of the Coverage Study
Agajanian, R.
Agarwal, A.
Agarwal, A. M.
Agarwal, A. M.
Agarwal, A.
Agarwal, B.
Agarwal, I.
Agarwal, M.
Agarwal, N.
Agarwal, P.
Agarwal, R.
Agarwal, S.
Agarwal, V.
Agashe, S.
Agathangelidis, A.
631 - Autonomous BCR Signaling and Genetic Aberrations in CLL-Phenotype Monoclonal B Lymphocytosis in Siblings of CLL Patients
745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21R110
745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21R110
Agathocleous, M.
Agathon, D.
Agbedia, O. O.
Agbor-Enoh, S.
Ageno, W.
Aggarwal, A.
Aggarwal, N.
193 - JAK 1/2 Inhibition Preserves Hematopoietic Progenitor and Stem Cells, Prevents Aplasia, Inhibits Pro-Inflammatory Cytokines, and Prolongs Survival in Murine Immune Bone Marrow Failure
2311 - Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
2563 - Ruxolitinib Stimulates Expansion of Regulatory T Cells in Murine Immune Bone Marrow Failure
2583 - Characterizing Immunodeficiency in Patients with Telomere Biology Disorders
2311 - Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
2563 - Ruxolitinib Stimulates Expansion of Regulatory T Cells in Murine Immune Bone Marrow Failure
2583 - Characterizing Immunodeficiency in Patients with Telomere Biology Disorders
Aggarwal, S.
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
Aggelakopoulou, M.
Agha, M.
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2736 - Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1st Induction Regimen
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
2736 - Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1st Induction Regimen
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Agirre, X.
Agius, M. P.
102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
Agius, R.
Agliardi, G.
Agnarsson, B. A.
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Agnelli, G.
Agnelli, L.
260 - A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with in-Vivo CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy
3005 - Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
3005 - Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
Agodoa, I.
Agostinelli, C.
Agoulnik, S.
Agrawal, A. K.
Agrawal, A. K.
Agrawal, N.
1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
Agrawal, P.
Agrawal, S. G.
Agrawal Singh, S.
Agrawal, V.
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Agte, S.
Aguado, B.
Aguayo-Hiraldo, P.
Aguennouz, M.
Aguet, F.
102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
Aguiar, M.
Aguiar, R.
705 - Perturbation of Intermediary Metabolism Inhibits Glycolysis, Oxidative Phosphorylation, Amino Acid Synthesis and Prevents Lymphoma Development in Mice
846 - Alpha-Ketoglutarate Suppresses MYC and mTORC1 and Displays Anti-Lymphoma Activity
2943 - Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
846 - Alpha-Ketoglutarate Suppresses MYC and mTORC1 and Displays Anti-Lymphoma Activity
2943 - Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
Aguila, S.
Aguilar, A.
Aguilar, B.
Aguilar, D. V.
Aguilar Neuville, P.
Aguilar, R.
Aguilar, R.
Aguilar, S.
Aguilar-Navarro, A.
Aguilera, C.
Aguirre, J. D.
Aguirre, L. E. E.
463 - A Product of “Clash of Titans” or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome
465 - Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
604 - Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351
1755 - Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes
2794 - Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
3073 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
3076 - Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
3099 - Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
4410 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
4414 - Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features
465 - Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
604 - Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351
1755 - Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes
2794 - Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
3073 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
3076 - Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
3099 - Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
4410 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
4414 - Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features
Agwu, C.
Agyekum, R. S.
Agyemang, E.
3239 - A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Ahaneku, H.
Ahle, G.
Ahlgren, L.
Ahlstrom, J. M.
3175 - Physical Activity in Patients with Monoclonal Gammopathies – a Healthtree Cure Hub Study
3194 - A Retrospective Comparison of the Side Effect Prevalence and Severity of Multiple Myeloma Triplet Vs Quadruplet Induction Therapy
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
4915 - The Top Concerns at and Since Diagnosis: Standard v. High Risk Myeloma Patients
3194 - A Retrospective Comparison of the Side Effect Prevalence and Severity of Multiple Myeloma Triplet Vs Quadruplet Induction Therapy
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
4915 - The Top Concerns at and Since Diagnosis: Standard v. High Risk Myeloma Patients
Ahluwalia, M.
Ahmad, A.
Ahmad, A.
Ahmad, I.
Ahmad, S.
Ahmann, G. J.
1821 - Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
Ahmann, J. M.
Ahmari, A. A.
Ahmed, E. H.
Ahmed, E. H.
Ahmed, J.
Ahmed, M.
Ahmed, N.
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
Ahmed, R.
Ahmed, R.
1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
Ahmed, S.
168 - Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
848 - Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies
960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin
1623 - Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy
2024 - Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
2041 - Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy
2271 - Risk of Pneumonitis with Immune Checkpoint Inhibitors in Hodgkin’s Lymphoma and Other Hematologic Malignancies: A Retrospective Review from Pharmacovigilance
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
3337 - Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
3353 - Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center
3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
3544 - Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
4676 - Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy
4900 - Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
848 - Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies
960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin
1623 - Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy
2024 - Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
2041 - Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy
2271 - Risk of Pneumonitis with Immune Checkpoint Inhibitors in Hodgkin’s Lymphoma and Other Hematologic Malignancies: A Retrospective Review from Pharmacovigilance
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
3337 - Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
3353 - Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center
3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
3544 - Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
4676 - Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy
4900 - Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections
Ahmed, S.
Ahmed, T.
AhmedRabie, A.
Ahn, I. E.
344 - Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1798 - Ibrutinib-Associated Sudden Death in Patients with CLL
1813 - Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
1798 - Ibrutinib-Associated Sudden Death in Patients with CLL
1813 - Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
Ahn, J. S.
424 - Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World
2715 - Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine
4306 - Prognostic Significance of 18f-FDG PET/CT in the Treatment of Primary Central Nervous System Lymphoma
2715 - Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine
4306 - Prognostic Significance of 18f-FDG PET/CT in the Treatment of Primary Central Nervous System Lymphoma
Ahn, K. J.
Ahn, S. Y.
424 - Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World
2715 - Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine
4306 - Prognostic Significance of 18f-FDG PET/CT in the Treatment of Primary Central Nervous System Lymphoma
2715 - Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine
4306 - Prognostic Significance of 18f-FDG PET/CT in the Treatment of Primary Central Nervous System Lymphoma
Ahn, S.
Ahn, W. K.
Ahnstrom, J.
Ahsan, A.
Ahuja, S.
1163 - Preferential Inheritance in Hemophilia
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
3563 - Reproductive Health Needs in Patients with Bleeding Disorders
3705 - Influence of Weather Patterns and Changes on Sickle Cell Disease Vaso-Occlusive Episodes and Acute Chest Syndrome: A Nationwide Sample Analysis
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
3563 - Reproductive Health Needs in Patients with Bleeding Disorders
3705 - Influence of Weather Patterns and Changes on Sickle Cell Disease Vaso-Occlusive Episodes and Acute Chest Syndrome: A Nationwide Sample Analysis
Ai, J.
1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
2313 - Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience
3637 - Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia
4727 - Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study
4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
2313 - Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience
3637 - Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia
4727 - Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study
4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
Ai, W. Z.
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
Aiello, T. F.
Aifantis, I.
Aifantis, I.
Aigner, M.
Ailawadhi, M.
Ailawadhi, S.
768 - Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma
1878 - Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk
1896 - Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib
1938 - Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
2218 - Advancing CAR T-Cell Care in Relapsed/Refractory Multiple Myeloma: Insights from a Collaborative Quality Improvement Initiative
2310 - Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020
3208 - Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment
3220 - Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
3589 - Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States
3612 - Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
4203 - Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4446 - Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4564 - Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
- Discuss approaches to improve enrollment and outcomes
1878 - Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk
1896 - Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib
1938 - Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
2218 - Advancing CAR T-Cell Care in Relapsed/Refractory Multiple Myeloma: Insights from a Collaborative Quality Improvement Initiative
2310 - Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020
3208 - Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment
3220 - Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
3589 - Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States
3612 - Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
4203 - Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4446 - Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4564 - Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
- Discuss approaches to improve enrollment and outcomes
Ailts, I.
Aiman, W.
Aimaz, A.
Ainciburu, M.
Aiolfi, R.
Airaud, F.
Aitken, R.
Aittokallio, T.
Aiuti, A.
Aiwuyo, H.
Aizenas, M.
Akahane, D.
Akahoshi, Y.
Akama, K.
Akarca, A.
Akard, L. P.
Akashi, K.
41 - The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53-Mutated AML
1282 - Suppressed Expression of ASCT1 Contributes to the Maintenance of Leukemia Stemness Via the Enhancement of Antioxidant Capacity
2662 - A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia
3941 - Single-Cell Transcriptome Reveals Comprehensive Immune Profiles of T Follicular Helper Cell Lymphoma
1282 - Suppressed Expression of ASCT1 Contributes to the Maintenance of Leukemia Stemness Via the Enhancement of Antioxidant Capacity
2662 - A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia
3941 - Single-Cell Transcriptome Reveals Comprehensive Immune Profiles of T Follicular Helper Cell Lymphoma
Akay, M.
Akazawa, R.
Akbar, M.
Akbar, U. A.
2522 - Efficacy and Safety of Tranexamic Acid for Reduction in Blood Transfusions in Patients Undergoing Major Non-Cardiac Surgeries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
4277 - R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
4925 - Second Primary Malignancy in Waldenström Macroglobulinemia: Insights from a Population-Based Analysis
4277 - R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
4925 - Second Primary Malignancy in Waldenström Macroglobulinemia: Insights from a Population-Based Analysis
Akdeniz, A.
Akel, S. M.
Akel, S.
Akerman, M.
Akhalkatsi, A.
Akheel, M. M.
3330 - Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
Akhlaghi, T.
Akhmedov, A.
Akhtar, O. S.
2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
4566 - A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
4566 - A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Akhtari, M.
Akiki, S. J.
Akiko, H.
Akilov, O. E.
2837 - Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma
2927 - Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
2927 - Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
Akin, C.
Akingbule, A.
Akinnola, K.
Akinsanya, K.
Akinsete, A. M.
Akinwumi, B.
Akinyemi, O.
Akiti, C.
Akiyama, H.
Akiyama, M.
Akladious, M.
Akpan, I. J.
Akram, M.
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
2030 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
2030 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Aktas-Samur, A.
642 - Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma
869 - Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors
1823 - Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma
1902 - In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis
3139 - Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma
869 - Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors
1823 - Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma
1902 - In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis
3139 - Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma
Akter, F.
Akter, M.
Aktypi, F.
Akuffo, A. A.
Akwaa, F.
Al Ali, N.
465 - Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1434 - Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
1491 - The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes
1755 - Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes
1757 - Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients
2318 - Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores
3073 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
3076 - Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
3084 - Clinical Characterization and Outcomes of Patients with NPM1-Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
3099 - Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
4406 - Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes
4410 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1434 - Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
1491 - The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes
1755 - Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes
1757 - Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients
2318 - Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores
3073 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
3076 - Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
3084 - Clinical Characterization and Outcomes of Patients with NPM1-Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
3099 - Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
4406 - Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes
4410 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
Al Ali, O.
Al Armashi, A. R.
600 - Racial Disparities in Mortality Trends from Acute Myeloid Leukemia: A Population-Based Study in the United States between 2000 and 2019
1006 - Autoimmune Hemolytic Anemia and Increased Stroke Risk in the United States: A Population-Based Study
1768 - The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020
1006 - Autoimmune Hemolytic Anemia and Increased Stroke Risk in the United States: A Population-Based Study
1768 - The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020
Al Baghdadi, T.
Al Darwish, M.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Al Hadidi, S.
106 - A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance
1909 - Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
2211 - Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis
2230 - Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals
3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
4545 - Variability of Definition of High-Risk Multiple Myeloma in Phase III Clinical Trials
4746 - Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
1909 - Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
2211 - Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis
2230 - Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals
3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
4545 - Variability of Definition of High-Risk Multiple Myeloma in Phase III Clinical Trials
4746 - Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
Al Hamed, R.
268 - Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
Al Khuridah, Z.
Al Malki, M. M.
770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1946 - Novel Tissue-Specific Targeted Radiation Delivery Reduces GI Injury and T Cell Trafficking Attenuating Allogeneic Immune Attack to Reduce GvHD in a Murine BMT Model
1972 - Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant
2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3325 - Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3379 - Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
3382 - Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
- New Strategies for Mismatched Unrelated Donors
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1946 - Novel Tissue-Specific Targeted Radiation Delivery Reduces GI Injury and T Cell Trafficking Attenuating Allogeneic Immune Attack to Reduce GvHD in a Murine BMT Model
1972 - Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant
2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3325 - Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3379 - Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
3382 - Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
- New Strategies for Mismatched Unrelated Donors
AL Malki, M. M.
2061 - Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Al Manea, A.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Al Raizah, A.
al Sabty, I.
Al Saeed, H. H.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Al Sagheer, T.
Al Saleh, A. S.
Al Zayed, A. H.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Al Zubaidi, A.
600 - Racial Disparities in Mortality Trends from Acute Myeloid Leukemia: A Population-Based Study in the United States between 2000 and 2019
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020
Al-Abayechi, A.
852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)
Al-Ajami, A.
Al-Akioui, K.
1997 - A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
4704 - Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism
4704 - Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism
Al-Ali, H. K.
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
Al-Ali, H. K.
627 - Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
3028 - Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum
3028 - Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum
Al-Ansari, H. Y.
Al-Athamen, K.
Al-Banaa, K.
Al-Dakkak, I.
Al-Hattab, E.
Al-Homsi, A. S.
Al-Huniti, A.
Al-Kadhimi, Z. S.
Al-Kaisi, F.
Al-Kali, A.
461 - ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
854 - Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
1715 - Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
4321 - Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
854 - Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
1715 - Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
4321 - Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Al-Kateb, H.
Al-Kindi, S.
Al-mansour, M.
Al-Mansour, Z.
2237 - Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Al-Mashdali, A. F.
Al-Ramahi, J. S.
Al-Samkari, H.
3 - Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
19 - Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Persistent, Isolated Mild Thrombocytopenia
506 - Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
592 - A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia
1021 - Mitapivat Improves Iron Overload in Patients with Pyruvate Kinase Deficiency
1030 - Mitapivat Improves Markers of Erythropoietic Activity in Long-Term Study of Adults with Alpha- or Beta-Non-Transfusion-Dependent Thalassemia
1773 - A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
3644 - Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients with Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response
4803 - A Machine-Learning Derived Red Blood Cell Morphology Tool Enables Differential Diagnosis and Novel Single-Cell Analyses
- Chemotherapy-Induced Thrombocytopenia
19 - Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Persistent, Isolated Mild Thrombocytopenia
506 - Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
592 - A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia
1021 - Mitapivat Improves Iron Overload in Patients with Pyruvate Kinase Deficiency
1030 - Mitapivat Improves Markers of Erythropoietic Activity in Long-Term Study of Adults with Alpha- or Beta-Non-Transfusion-Dependent Thalassemia
1773 - A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
3644 - Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients with Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response
4803 - A Machine-Learning Derived Red Blood Cell Morphology Tool Enables Differential Diagnosis and Novel Single-Cell Analyses
- Chemotherapy-Induced Thrombocytopenia
Al-Share, B.
Al-Tabaa, Y.
Al-Yafeai, Z.
Alabdulwahab, A. S.
Alabed, H. B.
Alabrach, Y.
Alacacıoğlu, İ.
Aladjidi, N.
Alagar, M.
Alahmari, B.
Alakel, N.
4 - In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
53 - Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
53 - Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
Alam, S.
Alameh, M. G.
Alamo, E.
Alanazi, T.
Alaniz, Z.
Alapa, M.
1682 - Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
3143 - Suppression of Myeloid Cell–Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)
3143 - Suppression of Myeloid Cell–Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)
Alapat, D.
Alapi, K. Z.
Alarcon Tomas, A.
263 - Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy
4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
Alarcon Tomas, A.
Alarcon Tomas, A.
Alashkar, F.
Alaskar, A.
Alaterre, E.
Alatrash, G.
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3290 - Targeting Myeloid Leukemia Using Novel TCR-like Chimeric Antigen Receptor-T Cells Against Cathepsin G
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
3979 - Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease
4033 - Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse
4081 - Humanized T Cell Receptor-like Antibody Hu8F4 Reduces Leukemia By Fc-Mediated Mechanism
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes
4725 - Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4764 - Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3290 - Targeting Myeloid Leukemia Using Novel TCR-like Chimeric Antigen Receptor-T Cells Against Cathepsin G
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
3979 - Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease
4033 - Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse
4081 - Humanized T Cell Receptor-like Antibody Hu8F4 Reduces Leukemia By Fc-Mediated Mechanism
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes
4725 - Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4764 - Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
Alavi, A.
282 - HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?
2140 - Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)
2256 - National Burden of Encapsulated Bacterial Infections in Sickle Cell Disease
3366 - Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin’s Lymphoma?
2140 - Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)
2256 - National Burden of Encapsulated Bacterial Infections in Sickle Cell Disease
3366 - Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin’s Lymphoma?
Albabtain, A.
Albagshi, M.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Albanese, A.
109 - Single-Cell RNA-Seq Reveals an Interferon-Driven Inflammatory CD4 Naïve T Cell Subpopulation at Day 100 in Hematopoietic Stem Cell Transplant Patients That Ultimately Develop Chronic Gvhd
111 - Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial
165 - Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
111 - Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial
165 - Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
Albano, F.
Albanyan, O.
264 - The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
1987 - Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
1987 - Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
Albanyan, O.
Albasanz-Puig, A.
Albeituni, S.
Albeituni, S.
Alberge, J. B.
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1826 - TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1
1828 - Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
1826 - TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1
1828 - Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
Albert, C.
Alberti, C.
Alberti, G.
Alberti Violetti, S.
Albertini, A.
Alberto, T.
Alberto, V.
Albertsen, B. K.
Albinger, N.
Albitar, M.
1543 - Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity
2076 - Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Gvhd (aGVHD) and Overall Survival after Allogeneic HSC Transplantation
2789 - DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
3488 - Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA
2076 - Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Gvhd (aGVHD) and Overall Survival after Allogeneic HSC Transplantation
2789 - DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
3488 - Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA
Albo, C.
Albuquerque, A.
Alcaide, M.
Alcalá, M.
Alcalde, P.
Alcantara, M.
Alcazar Ylizaliturri, J. L.
Alcedo Andrade, P. E.
Alcivar, L. M.
Alcoceba, M.
Alcoceba, M.
Alda Alvarez, O.
Aldamiz-Echevarría, T.
Aldapt, M. B.
Aldebert, C.
Alderfer, M. A.
Alderson, R. F.
Alderuccio, J. P.
2172 - Calculation of Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma Using a Deep Learning-Aided Automated Method
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
4207 - Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
4207 - Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
Aldoss, I.
63 - The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
216 - Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2732 - Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
216 - Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2732 - Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
AlDoughaim, M.
Alduaij, W.
AlDubayan, S. H.
Alegre, A.
118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
1881 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
1921 - Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
3536 - COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
1881 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
1921 - Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
3536 - COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
Alegre, A.
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021
4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021
Alegria, V. R.
1938 - Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
4203 - Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
4446 - Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)
4564 - Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
4203 - Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
4446 - Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)
4564 - Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
Alejandro, M.
Alejos Castillo, D. A.
Aleman, A.
249 - Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
1824 - Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment
1903 - Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
1824 - Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment
1903 - Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
Aleman, A.
Alemany, M.
Alemdehy, M. F.
Alemu, L.
Alencar, A. J.
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
1644 - Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4433 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
1644 - Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4433 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
Alessandria, B.
1528 - Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial
Alessi, H.
Alex H, C.
Alexander, D.
Alexander, J.
Alexe, G.
1500 - Proteomic Characterization of Acute Myeloid Leukemia
2154 - Breaking the Pump: Targeting the Sodium-Potassium Pump As a Therapeutic Strategy in Acute Myeloid Leukemia
2603 - Mechanisms of the CBFA2T3-GLIS2 Fusion in AML Maintenance
3471 - DHODH: A Promising New Therapeutic Target in Pediatric T-ALL
2154 - Breaking the Pump: Targeting the Sodium-Potassium Pump As a Therapeutic Strategy in Acute Myeloid Leukemia
2603 - Mechanisms of the CBFA2T3-GLIS2 Fusion in AML Maintenance
3471 - DHODH: A Promising New Therapeutic Target in Pediatric T-ALL
Alexeeva, V.
Alexis, K.
Alfar, H.
Alfar, R.
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
Alfaro Moya, T.
Alfonso, G.
Alfonso Pierola, A.
Alfonso-Pierola, A.
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1751 - Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression
3190 - 11c-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18f-FDG PET/CT and Prognostic Value Evaluation
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1751 - Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression
3190 - 11c-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18f-FDG PET/CT and Prognostic Value Evaluation
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Alfraih, F. A.
Alfred, T.
Algarotti, A.
Algarra, L.
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Algave, M.
Algeri, M.
775 - Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
3279 - CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia
4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
3279 - CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia
4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD
Algrin, C.
Algrin, C.
Alhaj Moustafa, M.
3220 - Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis
4235 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Primary Cutaneous CD30+ T-Cell Lymphoma: National Cancer Database Analysis (2004-2018)
4238 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Lymphocyte-Depleted Hodgkin’s Lymphoma: National Cancer Database Analysis (2004-2018)
4235 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Primary Cutaneous CD30+ T-Cell Lymphoma: National Cancer Database Analysis (2004-2018)
4238 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Lymphocyte-Depleted Hodgkin’s Lymphoma: National Cancer Database Analysis (2004-2018)
Alhakami, F.
Alhamadani, N.
2663 - Bruton’s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
3973 - Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
3973 - Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background
Alharbi, A.
Alharbi, A.
Alharbi, S.
Alharthy, H.
1404 - Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study
4067 - Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study
4067 - Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study
Alhazmi, I.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Alho, A. C.
Alhomoud, M.
484 - Impact of Epichaperome Inhibitor PU-H71 on Anti-Tumor T Cell Responses and Its Implications for Immune and Cellular Therapy
1971 - Low-Dose Radiation Improves Anti-CD19 CAR T-Cells Efficacy in Diffuse Large B-Cell Lymphoma through Fas/FasL Pathway
3375 - Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial
1971 - Low-Dose Radiation Improves Anti-CD19 CAR T-Cells Efficacy in Diffuse Large B-Cell Lymphoma through Fas/FasL Pathway
3375 - Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial
Ali, A. M.
Ali, E. A.
Ali, F.
Ali, H.
236 - Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
771 - Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
1714 - A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)
1734 - A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis
2061 - Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
771 - Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
1714 - A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)
1734 - A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis
2061 - Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
Ali, M. A.
Ali, M. A.
Ali, M. F.
Ali, N. D.
Ali, N. A.
Ali, R.
Ali, R.
Ali, S.
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
Ali, S.
1102 - Circulating B-Cell Precursor Cells As Potential Diagnostic and Therapeutic Biomarker in Patients with WHIM Syndrome
2407 - Prevalence of Chronic Neutropenic Disorders in the United States: A Retrospective Analysis of a Large Claims Database
3575 - Patient and Health Care Professional Perspectives on Quality of Life and Unmet Needs of People with Chronic Neutropenia: A Survey-Based Assessment
2407 - Prevalence of Chronic Neutropenic Disorders in the United States: A Retrospective Analysis of a Large Claims Database
3575 - Patient and Health Care Professional Perspectives on Quality of Life and Unmet Needs of People with Chronic Neutropenia: A Survey-Based Assessment
Aliazis, K.
Alibert, L.
Alibhai, S.
Alig, S. K.
72 - Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
2849 - Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
2849 - Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
Alignani, D.
99 - Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
3278 - Identification of Molecular Mechanisms Governing CAR-T Cell Response in MM Patients Using Single Cell Transcriptomics
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
3278 - Identification of Molecular Mechanisms Governing CAR-T Cell Response in MM Patients Using Single Cell Transcriptomics
Alija, B.
284 - Dysplastic Erythropoiesis in Stag2 Loss Exhibits Defective Nuclear Condensation and Hemophagocytosis
3908 - Cohesin Dependency in Npm1c/+ and Flt3-ITD Mutant Hematopoietic Stem and Progenitor Cells
4810 - High Throughput Epigenomic Mapping of Hematopoietic Stem and Progenitor Cells Using Low Cell Input Acoustic Enhanced Immunoprecipitation
3908 - Cohesin Dependency in Npm1c/+ and Flt3-ITD Mutant Hematopoietic Stem and Progenitor Cells
4810 - High Throughput Epigenomic Mapping of Hematopoietic Stem and Progenitor Cells Using Low Cell Input Acoustic Enhanced Immunoprecipitation
Alikarami, F.
Alikhan, R.
Alili, J. M.
Alilovic, K.
Alimi, A.
Alinari, L.
276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD+ Acute Myeloid Leukemia
704 - The FOXO1TAD-p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma
1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
2681 - Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)
2839 - Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
3328 - A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma
704 - The FOXO1TAD-p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma
1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
2681 - Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)
2839 - Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
3328 - A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma
Aliouat, A.
Alipour, E.
Alivernini, S.
Alizadeh, A. A.
72 - Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders
322 - MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
1519 - Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
2849 - Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
2872 - Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
4219 - Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma
4807 - Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study
322 - MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
1519 - Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
2849 - Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
2872 - Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
4219 - Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma
4807 - Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study
Alizadeh Zeinabad, H.
Alizee, J.
Aljama, M. A.
Aljama, M. A.
Aljawai, Y. M.
Aljoufi, A.
Aljubour, Z.
Aljurf, M.
986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
2569 - Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4740 - Utility and Validity of Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
2569 - Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4740 - Utility and Validity of Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population
Alkaabba, F.
1404 - Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study
4067 - Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study
4067 - Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study
Alkassim, R.
Alkhaldi, H.
Alkharabsheh, O.
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3593 - Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3593 - Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway
Alkhateeb, H. B.
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
4321 - Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
4321 - Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
Alkhraisat, S.
Alkrekshi, A.
600 - Racial Disparities in Mortality Trends from Acute Myeloid Leukemia: A Population-Based Study in the United States between 2000 and 2019
1006 - Autoimmune Hemolytic Anemia and Increased Stroke Risk in the United States: A Population-Based Study
1768 - The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020
1006 - Autoimmune Hemolytic Anemia and Increased Stroke Risk in the United States: A Population-Based Study
1768 - The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020
Allain, J.
Allain, V.
Allali, S.
Allam, R.
Allan, D.
Allan, D. S.
374 - Comparison of Allogeneic Hematopoietic Cell Transplantation Outcomes from Younger Matched Unrelated Donor Versus Older Sibling Donor for Acute Myeloid Leukemia
4729 - Younger Matched Unrelated Donors Confer a Decreased Relapse Risk As Compared to Older Sibling Donors for Adult B-Cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
4729 - Younger Matched Unrelated Donors Confer a Decreased Relapse Risk As Compared to Older Sibling Donors for Adult B-Cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Allan, J. N.
73 - Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma
92 - Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
92 - Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
Allard-Chamard, H.
Allawati, R.
Allbee-Johnson, M.
Allen, C.
703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma
1086 - Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study
1685 - Bone Marrow-Derived BRAFV600E-Mutated Cells Drive Neurodegeneration in a Mouse Model of Langerhans Cell Histiocytosis
1719 - Fine-Mapping of SMAD6 Sequence Data Identifies Additional Putative Risk Loci for Langerhans Cell Histiocytosis
2415 - Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US
4318 - Myeloid Progenitors Define Extent of Disease in Mouse Models of Histiocytic Disorders: BRAFV600E Expression in Monocyte Lineage Recapitulates Erdheim-Chester Phenotype
1086 - Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study
1685 - Bone Marrow-Derived BRAFV600E-Mutated Cells Drive Neurodegeneration in a Mouse Model of Langerhans Cell Histiocytosis
1719 - Fine-Mapping of SMAD6 Sequence Data Identifies Additional Putative Risk Loci for Langerhans Cell Histiocytosis
2415 - Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US
4318 - Myeloid Progenitors Define Extent of Disease in Mouse Models of Histiocytic Disorders: BRAFV600E Expression in Monocyte Lineage Recapitulates Erdheim-Chester Phenotype
Allen, C. E.
Allen, C.
Allen, D. H.
Allen, E.
Allen, F.
Allen, H. E.
Allen, J. W.
Allen, J.
Allen, K.
Allen, M. J.
455 - Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms
1718 - Comprehensive Profiling of Clinical JAK2 Inhibitors in Myeloproliferative Neoplasms
2993 - Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies
1718 - Comprehensive Profiling of Clinical JAK2 Inhibitors in Myeloproliferative Neoplasms
2993 - Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies
Allen, P. B.
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
2926 - Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Real-World Retrospective Study
4219 - Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
2926 - Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Real-World Retrospective Study
4219 - Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
Allen, S. L.
1796 - Integrin Signaling Pathway Is Crucial for the Recently Divided Fraction of CLL Cells and Facilitates Cell Migration in a Disease Progressive Manner
3112 - CD8+ T Cells from Patients with CLL Show Evidence of Granzyme B and Perforin Cytotoxic Capacity, Which Is Enhanced upon Exposure to Exogenous IL2 and/or IL21
4131 - Whole Genome Sequencing Comparison of Acute Myeloid Leukemia at Presentation and Remission Predicts Patient Outcome
4429 - Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL
3112 - CD8+ T Cells from Patients with CLL Show Evidence of Granzyme B and Perforin Cytotoxic Capacity, Which Is Enhanced upon Exposure to Exogenous IL2 and/or IL21
4131 - Whole Genome Sequencing Comparison of Acute Myeloid Leukemia at Presentation and Remission Predicts Patient Outcome
4429 - Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL
Allenspach, E. J.
Allepuz, A.
1693 - Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
Allison, R. L.
Allman, A.
3261 - Graft-Versus-Host Disease Induces Immune Dysregulation through Irreversible Damage to Specialized Immune-Interacting Fibroblastic Stromal Cells in Secondary Lymphoid Organs
3276 - Fibroblastic Stromal Cells Expressing Delta-like Notch Ligands Control Extrathymic T Cell Development in Mesenteric Lymph Nodes
3276 - Fibroblastic Stromal Cells Expressing Delta-like Notch Ligands Control Extrathymic T Cell Development in Mesenteric Lymph Nodes
Allman, D.
Allmer, C.
Allred, J. B.
Allsup, D.
94 - Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
4450 - The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
4450 - The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis
Ally, S. A.
Almader-Douglas, D.
Almahallawy, H.
Almanaseer, A.
Almanza Huante, E.
Almarza, E.
Almasry, M.
Almasy, L.
1188 - The Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) 353 R>q in the Coagulation Factor VII (FVII) Gene, F7, is Associated with Decreased Plasma FVII Levels and a Decreased Risk of Coronary Heart Disease (CHD) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas
Almeida, A. D.
Almeida, D. R. D.
Almeida Fonseca, T.
Almeida, M. A.
1188 - The Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) 353 R>q in the Coagulation Factor VII (FVII) Gene, F7, is Associated with Decreased Plasma FVII Levels and a Decreased Risk of Coronary Heart Disease (CHD) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas
Almeida-Porada, M. G.
Almhareb, F.
986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4740 - Utility and Validity of Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4740 - Utility and Validity of Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population
Almosailleakh, M.
Alnegheimish, N.
Alnemri, A.
Alnima, T.
Alnimer, Y.
Aloisi, T.
Alomran, D. M.
Alonso Alonso, A.
Alonso, C. D.
Alonso Dominguez, J. M.
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
3614 - End-of-Life Care in Hospitalized Patients with Hematologic Malignancies: A Retrospective Unicentric Study
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
3614 - End-of-Life Care in Hospitalized Patients with Hematologic Malignancies: A Retrospective Unicentric Study
Alonso Fernández, R.
Alonso, J. M.
Alonso, J. M.
Alonso, P.
Alonso Prieto, C.
Alonso-Dominguez, J. M.
Alonso-Dominguez, J. M.
Alonzo, T. A.
306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
422 - Distinct Latent Trajectory Phenotypes of Left Ventricular Function Associated with Differential Survival Among Children Treated for Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
4955 - Septic Shock and Septic Shock Mortality in Relation to Social Disorganization Index Among Children Being Treated for De Novo Acute Myeloid Leukemia on COG Clinical Trials
422 - Distinct Latent Trajectory Phenotypes of Left Ventricular Function Associated with Differential Survival Among Children Treated for Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
4955 - Septic Shock and Septic Shock Mortality in Relation to Social Disorganization Index Among Children Being Treated for De Novo Acute Myeloid Leukemia on COG Clinical Trials
Alotaibi, A. S.
Alousi, A. M.
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
2125 - Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3426 - Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond
4719 - The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
4725 - Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4764 - Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
2125 - Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3426 - Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond
4719 - The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
4725 - Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4764 - Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Alpern, E.
Alquezar-Artieda, N.
Alrawashdh, N.
889 - Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
3600 - Racial/Ethnic, Sex, and Income Disparities in Overall Survival (OS) in Chronic Lymphocytic Leukemia (CLL) Patients in the Era of Targeted Therapy: Surveillance, Epidemiology, and End Results (SEER) Registry Analysis (2009-2019)
3600 - Racial/Ethnic, Sex, and Income Disparities in Overall Survival (OS) in Chronic Lymphocytic Leukemia (CLL) Patients in the Era of Targeted Therapy: Surveillance, Epidemiology, and End Results (SEER) Registry Analysis (2009-2019)
Alsadhan, A.
Alsadi, H. M.
Alsafadi, S.
Alshaibani, A.
Alshreef, A.
Alsibai, R.
Alsina, L.
Alsina, M.
252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2118 - Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
2268 - Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
3251 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3355 - Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient’s Monitoring after CAR T-Cell Therapy
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4706 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2118 - Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
2268 - Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
3251 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3355 - Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient’s Monitoring after CAR T-Cell Therapy
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4706 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
Alsinet, C.
Alson, T.
Alsuhaibani, A.
Alten, J.
4136 - BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease
4139 - Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
4139 - Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
Althaus, K.
Althoff, M. J.
Althouse, A. D.
Altimiras, L.
Altman, J. K.
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
64 - Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
421 - A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial
933 - Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax
2656 - Synthetic Lipid Nanoparticles Actively Target Acute Myeloid Leukemia (AML) Cells and Induce Ferroptosis through Decreased Expression of Glutathione Peroxidase 4
2700 - Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML
2767 - A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
4072 - Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4088 - A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
64 - Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
421 - A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial
933 - Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax
2656 - Synthetic Lipid Nanoparticles Actively Target Acute Myeloid Leukemia (AML) Cells and Induce Ferroptosis through Decreased Expression of Glutathione Peroxidase 4
2700 - Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML
2767 - A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
4072 - Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4088 - A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
Altmann, H.
Altmeyer, S.
Altreuter, J.
Altrock, E.
1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms
1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
Altynova, E. S.
Alugubelli, R. R.
Alugubelli, R. R.
Alunno, L.
Aluri, S.
Alvarado, M.
2272 - Hematopoietic Stem Cell Transplantation Activity for Lymphoma: A Multicentric Study By the Transplantation and Cellular Therapy Mexican Working Group
3891 - Multi-Center Analysis of Clinical Characteristics, Outcomes and Overall Survival of an Under-Studied Entity: Paroxysmal Nocturnal Hemoglobinuria Associated with Bone Marrow Disorder
3891 - Multi-Center Analysis of Clinical Characteristics, Outcomes and Overall Survival of an Under-Studied Entity: Paroxysmal Nocturnal Hemoglobinuria Associated with Bone Marrow Disorder
Alvarado, Y.
84 - Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
1432 - Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials
1441 - Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
1696 - More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
1758 - Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
4059 - A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up
4069 - A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
4078 - Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
4392 - Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure
95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
1432 - Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials
1441 - Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
1696 - More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
1758 - Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
4059 - A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up
4069 - A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
4078 - Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
4392 - Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure
Alvares Borges, G.
Alvarez Calderon, F.
359 - A Novel Human OX40L-CAR-Treg Specifically Targets Activated Antigen-Presenting Cells and Effectively Controls T Cell Alloreactivity and Xeno-GvHD
482 - CAR-T Cell Infusion Results in Activation of CD160+/NKG2D+/CCL5+ Non-CAR CD8+ Cytotoxic ‘Bystander’ T Cells in Both Non-Human Primates (NHP) and Patients Receiving B-Cell-Directed CAR-Ts
482 - CAR-T Cell Infusion Results in Activation of CD160+/NKG2D+/CCL5+ Non-CAR CD8+ Cytotoxic ‘Bystander’ T Cells in Both Non-Human Primates (NHP) and Patients Receiving B-Cell-Directed CAR-Ts
Álvarez, E.
Álvarez, E.
Alvarez, H.
Alvarez, J.
3891 - Multi-Center Analysis of Clinical Characteristics, Outcomes and Overall Survival of an Under-Studied Entity: Paroxysmal Nocturnal Hemoglobinuria Associated with Bone Marrow Disorder
4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Alvarez, M. A.
118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
1194 - Machine Learning Model Defines Higher Risk of Venous Thromboembolism in Young Adults with Multiple Myeloma
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
1194 - Machine Learning Model Defines Higher Risk of Venous Thromboembolism in Young Adults with Multiple Myeloma
Alvarez, M.
Alvarez, O. A.
Alvarez Román, M. T.
1113 - Predictive Value of Platelet Sequestration Studies in Splenectomy Response
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
2475 - Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
2475 - Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
Alvarez Saravia, D.
Alvarez-Fernández, C.
Alvarez-Larran, A.
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
1708 - Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
4319 - Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
1708 - Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
4319 - Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model
Alvarez-Ojeda, H.
Álvarez-Román, M. T.
Alvarez-Saravia, D.
Alves, D.
Alves, L. B.
Alwie, Y.
Aly, M.
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
2565 - Immune Checkpoint Molecules Regulate Paroxysmal Nocturnal Hemoglobinuria Clonal Evolution
3087 - Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome
3818 - Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs
3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting
3955 - Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
2565 - Immune Checkpoint Molecules Regulate Paroxysmal Nocturnal Hemoglobinuria Clonal Evolution
3087 - Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome
3818 - Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs
3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting
3955 - Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
Aly, M. M. M.
Alyea, III, E. P.
Alzahrani, A.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Alzahrani, H. A.
Alzahrani, M.
986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
3383 - Effect of ABO Mismatch and RBC Alloimmunization on the Outcomes of Patients with Sickle Cell Disease Undergoing Hematopoietic Stem Cell Transplantation
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
3383 - Effect of ABO Mismatch and RBC Alloimmunization on the Outcomes of Patients with Sickle Cell Disease Undergoing Hematopoietic Stem Cell Transplantation
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Alzaki, A.
Alzubi, J.
Amador, C.
843 - Co-Occurrence of TP53/PTEN and CCR4 genetic Alteration Deregulates TH-Cell Differentiation and Drives TH2-like Lymphomagenesis and T-Cell Signaling
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
Amador, L. F.
Amadori, S.
225 - Quantum-First Trial: FLT3-ITD–Specific MRD Clearance Is Associated with Improved Overall Survival
878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial
878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial
Amanam, I.
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
2061 - Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
2061 - Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
Amann, E.
Amann, M.
Amano, M.
Amano, T.
Amar, V.
Amara, C.
Amaral, F.
349 - Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
3951 - Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
3951 - Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia
Amarante, G. B.
Amaro, C. M.
Amatangelo, M.
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
Amaya, M. L.
1421 - Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study
2634 - Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells
2634 - Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells
Amaya, M. L.
Ambaglio, C.
Ambati, S. R.
444 - Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
949 - Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1–3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
3992 - Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach
949 - Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1–3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
3992 - Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach
Ambinder, A. J.
597 - Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
1468 - Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status
1470 - Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
4768 - Outcomes of Patients with TP53-Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)
1468 - Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status
1470 - Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
4768 - Outcomes of Patients with TP53-Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)
Ambinder, R. F.
763 - Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies – Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
Ambrose, E. E.
Ambrosino, N.
Amelunxen, E.
Amengual, J. E.
147 - First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade
954 - Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
1640 - Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder
1648 - Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder
4441 - Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience
954 - Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
1640 - Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder
1648 - Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder
4441 - Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience
Amer, M.
Ames, D. M.
Amigo, M. L.
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Amin, H.
461 - ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
854 - Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
854 - Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
Amin, N. E.
Amini, K.
Aminkeng, F.
Aminossadati, B.
Aminov, S.
Amiot, M.
Amit, O.
1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
4736 - Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes – a Single Center Longitudinal Cohort Analysis
4771 - Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis
4736 - Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes – a Single Center Longitudinal Cohort Analysis
4771 - Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis
Amler, S.
Ammad Ud Din, M.
2698 - The Impact of Chronic Kidney Disease on Hospitalization Outcomes in Patients Admitted with Acute Myeloid Leukemia: A Nationwide Analysis Using the National Inpatient Sample Database (2015-2019)
3666 - Complications during Delivery Hospitalizations in Women with Thalassemia: An Analysis of the National Inpatient Sample Database (2002-2019)
3666 - Complications during Delivery Hospitalizations in Women with Thalassemia: An Analysis of the National Inpatient Sample Database (2002-2019)
Ammann, E. M.
2283 - Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
2291 - Light-Chain Amyloidosis in Sweden (2011-2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients
4497 - Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age
2291 - Light-Chain Amyloidosis in Sweden (2011-2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients
4497 - Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age
Ammari, N.
Ammatuna, E.
523 - M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment
2787 - High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia
3960 - Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia
3970 - Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2-Mutant Acute Myeloid Leukemia
2787 - High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia
3960 - Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia
3970 - Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2-Mutant Acute Myeloid Leukemia
Ammerlaan, A. C.
3987 - Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – Results from the ITCC-059 Phase IA and Phase II Trial
4047 - Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results from the ITCC-059 Phase 1B Trial
4047 - Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results from the ITCC-059 Phase 1B Trial
Ammon, A.
Amoah, A.
2769 - Targeting the WT1mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia
3881 - Establishing an Easy-to-Use 3D BM Niche Model for the Co-Culture of Primary Bone Marrow Mesenchymal Stromal Cells (BM-MSC) with Hematopoietic Stem and Progenitor Cells (HSPC)
3881 - Establishing an Easy-to-Use 3D BM Niche Model for the Co-Culture of Primary Bone Marrow Mesenchymal Stromal Cells (BM-MSC) with Hematopoietic Stem and Progenitor Cells (HSPC)
Amodio, N.
Amoloja, T.
Amonoo, H. L.
Amoozgar, B.
Amorim, R.
Amorim, S.
Amos, C. I.
Amos, L. E.
Amos-Abanyie, E.
Amoura, Z.
Amoury, M.
Ampatzidou, M.
Amrein, P. C.
Amrolia, P. J.
997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
2132 - T-Cell Replete Unrelated Cord Blood Transplant Give Superior Outcomes to Other Donor Sources in High Risk and Relapsed/Refractory Paediatric Myeloid Malignancy
4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL
2132 - T-Cell Replete Unrelated Cord Blood Transplant Give Superior Outcomes to Other Donor Sources in High Risk and Relapsed/Refractory Paediatric Myeloid Malignancy
4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL
Amundson, M. R.
Amunts, A.
An, G.
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
1559 - Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study
1906 - The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma
3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment
3197 - Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
3229 - Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?
4498 - Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation
4749 - A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma
1559 - Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study
1906 - The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma
3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment
3197 - Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
3229 - Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?
4498 - Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation
4749 - A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma
An, H. Y.
An, H. H.
An, R.
2370 - Sickling Dynamics Differ Among the Different Sickle Cell Disease Genotypes
3485 - Paper-Based Microchip Electrophoresis Enabled First Point-of-Care Diagnostic Test for Beta-Thalassemia
3675 - Extracellular Vesicles from Sickle Red Blood Cells Activate Endothelial Cells and Trigger Von Willebrand Factor-Mediated Sickle Red Cell Adhesion
3687 - Membrane Bending Enhances Sulfatide Mediated Sickle Mature Erythrocyte Adhesion
3485 - Paper-Based Microchip Electrophoresis Enabled First Point-of-Care Diagnostic Test for Beta-Thalassemia
3675 - Extracellular Vesicles from Sickle Red Blood Cells Activate Endothelial Cells and Trigger Von Willebrand Factor-Mediated Sickle Red Cell Adhesion
3687 - Membrane Bending Enhances Sulfatide Mediated Sickle Mature Erythrocyte Adhesion
An, W.
An, W.
An, X.
1019 - Heme and Iron Aggravate Tissue Damage in Sickle Cell Disease By Driving Macrophage Functional Reprogramming through the Coordinated Suppression of Efferocytosis and Mitochondrial Metabolism
3662 - ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis
3662 - ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis
An, Z. Y.
Anabaraonye, N.
Anabtawi, N.
Anabtawi, N.
Anad, S.
Anagnostopoulos, A.
Anaissie, E. J.
Anampa-Guzman, A.
170 - Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2925 - Clinical Impact of the Intensity of Induction Regimens Prior to Consolidation in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma (PTCL)
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2925 - Clinical Impact of the Intensity of Induction Regimens Prior to Consolidation in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma (PTCL)
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
Anand, J.
Anand, P.
Anand, S. M.
Anand, V.
Ananth, S.
852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)
Ananthakrishnan, R.
361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
Ananthaneni, A.
Anany, M.
Anasetti, C.
365 - Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3412 - Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3412 - Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia
Anastasia, A.
Anastasopoulos, J.
Ancliff, P.
Andemariam, B.
677 - Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)
2375 - Active Study: Impact of Voxelotor on Sleep Quality, Physical Activity, and Patient-Reported Outcomes
2379 - ASCENT1: A Phase 2 Trial to Evaluate the Efficacy and Safety of Oral Decitabine–Tetrahydrouridine (NDec) in Patients with Sickle Cell Disease
3702 - Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor
3710 - Real-World Outcomes in Adult Sickle Cell Disease Patients Treated with Crizanlizumab, Voxelotor or Both
4820 - Clinical and Economic Outcomes in Patients with Transfusion-Dependent β-Thalassemia and Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Receiving Hematopoietic Stem Cell Transplants in the United States
2375 - Active Study: Impact of Voxelotor on Sleep Quality, Physical Activity, and Patient-Reported Outcomes
2379 - ASCENT1: A Phase 2 Trial to Evaluate the Efficacy and Safety of Oral Decitabine–Tetrahydrouridine (NDec) in Patients with Sickle Cell Disease
3702 - Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor
3710 - Real-World Outcomes in Adult Sickle Cell Disease Patients Treated with Crizanlizumab, Voxelotor or Both
4820 - Clinical and Economic Outcomes in Patients with Transfusion-Dependent β-Thalassemia and Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Receiving Hematopoietic Stem Cell Transplants in the United States
Andera, L.
Anderl, J.
Andernacht, K.
Andersen, A. P.
Andersen, C. L.
Andersen, C. R.
Andersen, J. T.
Andersen, M. H.
Andersen, M. K.
Andersen, Jr., M. J.
Andersen, M.
Andersen, N. F.
Andersen, T. L.
Anderson, A.
Anderson, A.
Anderson, D.
Anderson, G.
Anderson, G. A.
Anderson, G. S.
Anderson, G. J.
Anderson, K. E.
Anderson, K. C.
148 - Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma
241 - BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells
247 - Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
642 - Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
859 - Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients
1902 - In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
3193 - Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma
3197 - Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
3991 - 26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma
4456 - Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy
4471 - CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma
4472 - CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma
4478 - Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation
241 - BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells
247 - Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
642 - Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
859 - Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients
1902 - In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
3193 - Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma
3197 - Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
3991 - 26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma
4456 - Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy
4471 - CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma
4472 - CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma
4478 - Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation
Anderson, K.
Anderson, L.
Anderson, Jr., L. D.
364 - Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
473 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
868 - Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
3238 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
4560 - An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
473 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
868 - Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
3238 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
4560 - An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
Anderson, L.
Anderson, M. A.
75 - Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)
4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)
Anderson, M. A.
Anderson, M. W.
Anderson, M. B.
1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
Anderson, N.
Anderson, N. R.
Anderson, P. F.
Anderson, R.
Anderson, R.
Anderson, S.
Anderson, T.
3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
Anderson-Crannage, M.
Andersson, B. S.
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
Andersson, P. O.
Andersson, P.
3013 - Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions
4341 - XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use
4341 - XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use
Andersson, S.
3559 - Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study
3565 - Fitusiran Reaches People’s with Hemophilia and Their Caregivers’ Treatment Expectations: Qualitative Semi-Structured Interviews of Participants of ATLAS-OLE Trial (Interim analysis)
3565 - Fitusiran Reaches People’s with Hemophilia and Their Caregivers’ Treatment Expectations: Qualitative Semi-Structured Interviews of Participants of ATLAS-OLE Trial (Interim analysis)
Andersson, T. M.
Andina, N. D.
Andino, L.
2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4029 - Improvements in AML Treatment Outcomes By Twinning at the Instituto De Prevision Social Hospital in Paraguay
4029 - Improvements in AML Treatment Outcomes By Twinning at the Instituto De Prevision Social Hospital in Paraguay
Ando, J.
Ando, K.
853 - Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma
1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma
Andolfo, I.
Andolina, J. R.
Andorno, A.
Andorsky, D.
Andrade Campos, M. M.
Andrade, M.
Andrade-Campos, M. M.
Andrade-Martinez, M.
Andre, I.
Andre, M.
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1589 - Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1589 - Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up
André, M.
Andreadis, C.
316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
Andreatos, E.
Andreeff, M.
61 - Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
199 - C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
946 - Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax
1269 - Traceable Mouse Models for Tracking p53-Mutant Subclones in Acute Myeloid Leukemia
1320 - Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3-ITD/-TKD Mutant AML in a PDX Model
1335 - Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia
1449 - Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells
2610 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia
2638 - Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
2788 - Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
2812 - Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations
3000 - A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA
3956 - Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia
3958 - ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism
4078 - Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
199 - C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
946 - Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax
1269 - Traceable Mouse Models for Tracking p53-Mutant Subclones in Acute Myeloid Leukemia
1320 - Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3-ITD/-TKD Mutant AML in a PDX Model
1335 - Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia
1449 - Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells
2610 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia
2638 - Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
2788 - Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
2812 - Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations
3000 - A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA
3956 - Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia
3958 - ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism
4078 - Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Andreelli, F.
Andrei, P.
Andrés, C.
Andres, M.
Andres, O.
1108 - Gradually Increased Gpiib/Iiia Responsiveness from Preterm and Term Neonatal Infants to Adults Reveals a Complex Phenotypic Switch during Platelet Ontogenesis - Data from the Platelets in Neonatal Infants Study (PLINIUS)
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
Andresen, F.
Andrews, C.
Andrews, C.
1115 - Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
1372 - Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up
2691 - Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
1372 - Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up
2691 - Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
Andriani, A.
Andrieu, G. P.
Andrieux, G.
Andrieux, G.
Andritsos, L. A.
2891 - Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
2903 - Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
2903 - Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
Andruk, M.
Andryka, K.
Ang, J.
Ang, K. K.
Ang, P.
Angchaisuksiri, P.
Angchaisuksiri, P.
Angelidakis, G.
Angelillo-Scherrer, A.
693 - SLN140 a Small Interfering RNA Targeting Protein S Improves Hemostasis Potency in Hemophilia
1674 - Escape from Type II JAK2 Inhibition in MPN Depends on AXL/MAPK Activation and Is Targetable
2531 - Ribonuclease Inhibitor 1 (RNH1) Regulates Myeloid Lineage Choice through Cyclin-Dependent Kinase 1
3746 - A Role of Immunothrombosis in Acquired Antibody-Mediated Thrombophilia’s: Classical Complement and Neutrophil Activation in APS and HIT
3898 - Ribosome-Associated Protein Ribonuclease Inhibitor (RNH1) Regulates Hematopoietic Specific Translation
1674 - Escape from Type II JAK2 Inhibition in MPN Depends on AXL/MAPK Activation and Is Targetable
2531 - Ribonuclease Inhibitor 1 (RNH1) Regulates Myeloid Lineage Choice through Cyclin-Dependent Kinase 1
3746 - A Role of Immunothrombosis in Acquired Antibody-Mediated Thrombophilia’s: Classical Complement and Neutrophil Activation in APS and HIT
3898 - Ribosome-Associated Protein Ribonuclease Inhibitor (RNH1) Regulates Hematopoietic Specific Translation
Angelini, D. E.
590 - Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease
1199 - Efficacy of the Hepcon System in Reducing Hemorrhagic and Thrombotic Complications in Antiphospholipid Syndrome Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
4826 - Managing Kidney Disease in Patients with Sickle Cell Disease: A Quality Initiative at the Cleveland Clinic
1199 - Efficacy of the Hepcon System in Reducing Hemorrhagic and Thrombotic Complications in Antiphospholipid Syndrome Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
4826 - Managing Kidney Disease in Patients with Sickle Cell Disease: A Quality Initiative at the Cleveland Clinic
Angelini, G.
Angelini, S.
Angelis, N.
Angelopoulou, M. K.
Angelosanto, N.
2642 - Multiomics Analysis Confirms Effective Target Engagement for RVU120 – a First-in-Class CDK8/19 Kinase Inhibitor in AML and MR-MDS Patients and Reveals the Mechanism of Action
2771 - CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts
2771 - CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts
Angelucci, E.
2223 - PICC Insertion and Management in Hodgkin and NON-Hodgkin Lymphomas: A 13-YEARS Monocentric Experience
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
3447 - A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
3623 - Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program
4717 - Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
3447 - A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
3623 - Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program
4717 - Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study
Anghelescu, D.
Anghelina, M. I.
2891 - Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
2903 - Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
2903 - Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
Anghileri, E.
Angiolillo, A. L.
Angiulli, V.
Angona, A.
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
1708 - Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
2996 - Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
1708 - Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
2996 - Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
Angori, E.
Angove, R.
Anguiano, E.
Anguille, S.
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
4637 - Initial Clinical Results of Atalanta-1, a Phase I/II Trial of Point-of-Care Manufactured GLPG5101 (19CP02) in RR NHL
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
4637 - Initial Clinical Results of Atalanta-1, a Phase I/II Trial of Point-of-Care Manufactured GLPG5101 (19CP02) in RR NHL
Anguita Arance, M. M.
Angulo Salazar, M.
Anhuf, J.
Anhut, P.
Ankala, R.
Annan, A.
Annarapu, G. K.
Annunziata, M.
2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
Annunziato, F.
Annunzio, K.
154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1582 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma
4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1582 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma
4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
Anokhina, K.
Anosov, I.
Ansaldo, K.
Ansari, A.
Ansari, S.
Ansari-Lari, M. A.
Ansari-Pour, N.
Ansell, S. M.
18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
70 - IRF4 Shapes the Tumor Microenvironment of Follicular Lymphoma
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
728 - Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
1240 - Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2966 - Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
4156 - Molecular Landscape of Primary Refractory DLBCL
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
4745 - Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR- Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
70 - IRF4 Shapes the Tumor Microenvironment of Follicular Lymphoma
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
728 - Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
1240 - Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2966 - Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
4156 - Molecular Landscape of Primary Refractory DLBCL
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
4745 - Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR- Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
Ansermet, C.
Ansher, S.
Anstee, N. S.
1226 - Allogeneic Hematopoietic Cell Transplantation (HCT) and Impact on Clonal Haematopoiesis and Post-HCT Therapy-Related Myeloid Neoplasm in Heavily Treated and Poor Risk Patients with Plasma Cell Myeloma
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
Ansuinelli, M.
Ansuini, A.
Anthias, C.
2047 - Prevalence of Sars-Cov-2 in Stem Cell Donors from Anthony Nolan UK Stem Cell Registry: Sars-Cov-2 Testing Programme, Impact on Stem Cell Collections and Managing Risk Going Forward
3361 - Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes
4217 - Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital
3361 - Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes
4217 - Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital
Anthony, C.
Anthony, S. P.
3172 - LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity
4084 - LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)
4795 - Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia
4084 - LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)
4795 - Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia
Antic, D.
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1200 - Tissue Factor Positive Extracellular Vesicles and Risk of Thromboembolism in Diffuse Large B-Cell Lymphoma: A Prospective Exploratory Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1200 - Tissue Factor Positive Extracellular Vesicles and Risk of Thromboembolism in Diffuse Large B-Cell Lymphoma: A Prospective Exploratory Study
Antic, Z.
438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups
1503 - Mutational Mechanisms in Pediatric Acute Lymphoblastic Leukemia with Multiple Relapses
4139 - Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
1503 - Mutational Mechanisms in Pediatric Acute Lymphoblastic Leukemia with Multiple Relapses
4139 - Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
Antin, J. H.
377 - Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study
880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial
1262 - Outcomes of Hematologic Complications in Shwachman Diamond Syndrome: High Risk Features and Implications for Surveillance
2097 - Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd
880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial
1262 - Outcomes of Hematologic Complications in Shwachman Diamond Syndrome: High Risk Features and Implications for Surveillance
2097 - Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd
Antolini, L.
Antoñana-Vildosola, A.
Antonenas, V.
Antoniak, S.
Antonios, B.
Antoniou, E.
423 - Revision of Complete Remission Criteria in Pediatric AML
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2710 - Management and Outcome of Hyperleukocytosis As Early Complication in Childhood AML – an AML-BFM Experience
4104 - RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2710 - Management and Outcome of Hyperleukocytosis As Early Complication in Childhood AML – an AML-BFM Experience
4104 - RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group
Antoniou, P.
Antonissen, N. J.
Antony, C.
Antony, M. L.
Antovic, J.
Antun, A. G.
Antunes, L.
Antunes, V.
Antunovic, P.
Antypiuk, A.
1019 - Heme and Iron Aggravate Tissue Damage in Sickle Cell Disease By Driving Macrophage Functional Reprogramming through the Coordinated Suppression of Efferocytosis and Mitochondrial Metabolism
2337 - Differential Recovery of Macrophage Iron Deficiency By Oral Iron Formulations Determines Cell Inflammatory Response in Conditions of Iron Deficiency Anemia
2340 - Genetic Iron Overload Aggravates and Pharmacological Iron Restriction Improves MDS Pathophysiology in a Preclinical Mouse Model
2337 - Differential Recovery of Macrophage Iron Deficiency By Oral Iron Formulations Determines Cell Inflammatory Response in Conditions of Iron Deficiency Anemia
2340 - Genetic Iron Overload Aggravates and Pharmacological Iron Restriction Improves MDS Pathophysiology in a Preclinical Mouse Model
Antzoulatos, S.
Anuar, N.
Anuraj, A.
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
Anusim, N.
Anwar, A.
Anwer, F.
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
2221 - Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
2522 - Efficacy and Safety of Tranexamic Acid for Reduction in Blood Transfusions in Patients Undergoing Major Non-Cardiac Surgeries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
3211 - Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
3227 - Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients
3766 - Efficacy and Safety of Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Immune Thrombocytopenia
4277 - R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
4748 - Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4904 - Trends over Time in Overall Survival of Patients with Multiple Myeloma By Race/Ethnicity and By Comorbidity Status: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
4925 - Second Primary Malignancy in Waldenström Macroglobulinemia: Insights from a Population-Based Analysis
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
2221 - Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
2522 - Efficacy and Safety of Tranexamic Acid for Reduction in Blood Transfusions in Patients Undergoing Major Non-Cardiac Surgeries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
3211 - Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
3227 - Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients
3766 - Efficacy and Safety of Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Immune Thrombocytopenia
4277 - R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
4748 - Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4904 - Trends over Time in Overall Survival of Patients with Multiple Myeloma By Race/Ethnicity and By Comorbidity Status: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
4925 - Second Primary Malignancy in Waldenström Macroglobulinemia: Insights from a Population-Based Analysis
Anwer, F.
1868 - Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
Aoki, T.
71 - Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma
308 - Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma
844 - TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma
1548 - Spatial Protein Analysis of the Tumor Microenvironment and Biomarkers in Hodgkin’s Lymphoma
308 - Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma
844 - TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma
1548 - Spatial Protein Analysis of the Tumor Microenvironment and Biomarkers in Hodgkin’s Lymphoma
Aotsuka, N.
2053 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
4812 - A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
4812 - A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
Aoun, C.
Aoyama, K.
Apaflo, J. N.
Aparicio Pérez, C.
Apathy, R.
Apffel, A.
Aplenc, R.
422 - Distinct Latent Trajectory Phenotypes of Left Ventricular Function Associated with Differential Survival Among Children Treated for Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
943 - Single-Cell Map of Childhood Acute Myeloid Leukaemia Using Variational Auto-Encoders
983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
1486 - Proteotranscriptomic Strategy to Discover Acute Myeloid Leukemia Immunotherapy Targets
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2796 - Improved Relapse Prediction in Pediatric Acute Myeloid Leukemia By Deconvolving Lineage-Specific and Cancer-Specific Features in Single-Cell Data
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia
4955 - Septic Shock and Septic Shock Mortality in Relation to Social Disorganization Index Among Children Being Treated for De Novo Acute Myeloid Leukemia on COG Clinical Trials
943 - Single-Cell Map of Childhood Acute Myeloid Leukaemia Using Variational Auto-Encoders
983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
1486 - Proteotranscriptomic Strategy to Discover Acute Myeloid Leukemia Immunotherapy Targets
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2796 - Improved Relapse Prediction in Pediatric Acute Myeloid Leukemia By Deconvolving Lineage-Specific and Cancer-Specific Features in Single-Cell Data
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia
4955 - Septic Shock and Septic Shock Mortality in Relation to Social Disorganization Index Among Children Being Treated for De Novo Acute Myeloid Leukemia on COG Clinical Trials
Apodaca Chavez, E.
Apodaca, E. I.
Apostolakis, J.
Apostolidis, J.
Appelbaum, F. R.
Appelbaum, J. S.
57 - Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia
1385 - Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse
2708 - Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
1385 - Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse
2708 - Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
Apperley, J. F.
84 - Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
621 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3025 - Real-World Experience of Asciminib: Factors Associated with Response
4332 - Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study
- Treatment of CML in Pregnancy
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
621 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3025 - Real-World Experience of Asciminib: Factors Associated with Response
4332 - Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study
- Treatment of CML in Pregnancy
Appiah-Kubi, A.
886 - Assessing Multi-Level Barriers to Medication Adherence in Youth with Sickle Cell Disease Using Pharmacy-Based Prescription Refill Data
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
Aprile, A.
Apsel Winger, B.
Aptekar, J.
Aptekmann, A. A.
Aquaronne, D.
Aquila, R.
Aquilar, E.
Ara, T.
478 - Calcineurin Inhibitors Inhibit Tolerance Induction By Suppressing Terminal Differentiation of Donor Exhausted T Cells after Allogeneic SCT
974 - Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells
990 - Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
974 - Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells
990 - Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
Aracu, L.
Aradhya, A.
Arai, A.
Arai, A.
Arai, H.
Arai, K.
Arai, S.
110 - Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals
640 - Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
2090 - Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4719 - The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
640 - Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
2090 - Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4719 - The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
Arai, Y.
Arai, Y.
Araki, K.
Aral, B.
Arami, S.
Arana Yi, C.
Arand, J.
Arango, D.
Arango, J. E.
Arango Ossa, J. E.
Arango-Ossa, J. E.
495 - Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination
1579 - Long-Term Outcome of Patients with Follicular Lymphoma Is Not Fundamentally Affected By KMT2D, EZH2, and Crebbp Mutational Status
2827 - Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia
1579 - Long-Term Outcome of Patients with Follicular Lymphoma Is Not Fundamentally Affected By KMT2D, EZH2, and Crebbp Mutational Status
2827 - Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia
Aránguiz, N.
Aranha, M. P.
102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
Aratia, S.
671 - Take Control. Period. –Interactive Patient Education Website Enhances Adherence to Tranexamic Acid and Iron Supplementation in Women with Heavy Menstrual Bleeding
3804 - The Empower Study – Design of a Randomized Clinical Trial to Assess the Efficacy and Safety of a Plasma-Derived Von Willebrand Factor / Factor VIII Concentrate for Heavy Menstrual Bleeding in Women with Von Willebrand Disease
3804 - The Empower Study – Design of a Randomized Clinical Trial to Assess the Efficacy and Safety of a Plasma-Derived Von Willebrand Factor / Factor VIII Concentrate for Heavy Menstrual Bleeding in Women with Von Willebrand Disease
Araujo, C.
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
Araújo, J.
Araujo-Ayala, F.
Arbab, A.
Arber, D. A.
437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers
- Philosophy and Overview of the International Consensus Classification of Myeloid and Lymphoid Neoplasms
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers
- Philosophy and Overview of the International Consensus Classification of Myeloid and Lymphoid Neoplasms
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Arcaini, L.
233 - Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
1580 - Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study
1644 - Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
2895 - Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy
2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study
3038 - Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial
- Management of Marginal Zone Lymphoma
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
1580 - Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study
1644 - Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
2895 - Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy
2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study
3038 - Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial
- Management of Marginal Zone Lymphoma
Arcari, A.
733 - PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)
2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study
2972 - Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study
2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study
2972 - Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study
Arcarons, J.
2063 - Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT
2082 - Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT
3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis
2082 - Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT
3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis
Arcese, W.
Archambault, A.
Archer, D. R.
Archer, K. J.
536 - Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study
789 - Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
789 - Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
Archer, N. M.
887 - Increasing COVID-19 Vaccination Rates Amongst Children with Sickle Cell Disease: A Quality Improvement Project
2387 - Ketamine Use for Management of Vaso-Occlusive Pain in Children with Sickle Cell Disease
2393 - Natural History of Pediatric Patients with Sickle Cell Disease and Concurrent Cerebral Vasculopathies: Report of 62 Cases from a Single Institution
3525 - Improving Rates of Annual Transcranial Doppler Screening in Children with Sickle Cell Disease: A Quality Improvement Project
2387 - Ketamine Use for Management of Vaso-Occlusive Pain in Children with Sickle Cell Disease
2393 - Natural History of Pediatric Patients with Sickle Cell Disease and Concurrent Cerebral Vasculopathies: Report of 62 Cases from a Single Institution
3525 - Improving Rates of Annual Transcranial Doppler Screening in Children with Sickle Cell Disease: A Quality Improvement Project
Archer, T. C.
Archibald, W. J.
Arcila, M. E.
2862 - Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies
4128 - Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm
4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4128 - Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm
4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
Arciprete, F.
Arcos Campillo, J.
2264 - Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy
4936 - Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy
4936 - Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy
Arcudi, S.
Arcuri, L. J.
Arcuri, L.
Ardeshna, K.
Ardeshna, K. M.
607 - Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
4265 - Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
4265 - Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
Ardissino, G.
Arduini, S.
Ardura, M. I.
2206 - Fever and Neutropenia Management and Infectious Prevention Strategies in Children with Severe or Very Severe Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study
4842 - Infectious Disease Antimicrobial Prophylaxis Strategies in Children with Severe or Very Severe Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study
4842 - Infectious Disease Antimicrobial Prophylaxis Strategies in Children with Severe or Very Severe Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study
Arellano, M. L.
63 - The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2758 - A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2758 - A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Arellano, N. S.
Arellano-Rodrigo, E.
Arena, V.
Arenas, F.
Arends, C. M.
Arenillas, L.
Arentsen-Peters, S. T.
Arepally, G. M.
Areti, S. S.
Aretz, J.
Arevalo, M.
Arevalo-Vargas, I.
Arffman, M.
Argento, C.
Argnani, L.
Argüello, R. J.
1469 - Extracellular Vesicle-Based Liquid Biopsy Shows Clinical Relevance and Reveals Links with Single-Cell Metabolic Signature in Acute Myeloid Leukemia
4127 - Parallel Detection of Single-Cells and Extracellular Vesicles from Bone Marrow and Peripheral Blood Reveals Asymmetric Immunometabolic Profile in Acute Myeloid Leukemia
4127 - Parallel Detection of Single-Cells and Extracellular Vesicles from Bone Marrow and Peripheral Blood Reveals Asymmetric Immunometabolic Profile in Acute Myeloid Leukemia
Argueta, D. A.
177 - Modulation of Pain-Associated Behaviors in Sickle Mice Using Low-Intensity Transcranial Focused Ultrasound
1048 - Colchicine Reduces Inflammation in a Humanized Mouse Model of Sickle Cell Disease
2460 - Palmitoylethanolamide Attenuates Pain-like Behavior in Factor VIII Deficient Mice
3676 - Cannabidiol Attenuates Chronic and Acute Hyperalgesia in Sickle Mice By Reducing Inflammation and Oxidative Stress
1048 - Colchicine Reduces Inflammation in a Humanized Mouse Model of Sickle Cell Disease
2460 - Palmitoylethanolamide Attenuates Pain-like Behavior in Factor VIII Deficient Mice
3676 - Cannabidiol Attenuates Chronic and Acute Hyperalgesia in Sickle Mice By Reducing Inflammation and Oxidative Stress
Arguiñano, J. M.
99 - Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
4448 - Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
4448 - Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Arguiñano PEREZ, J. M.
Argyropoulos, K. V.
Arianna, S.
Arias-Espinosa, L.
Aribi, A.
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3382 - Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3382 - Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
Ariceta, B.
Aries, J.
829 - High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML
4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme
4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme
Arif, T.
Arikawa, Y.
Arildsen, M. A.
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
Arima, N.
Arima, Y.
Aristei, C.
879 - HLA-Matched Treg/Tcon Allogeneic Hematopoietic Cell Transplantation Is Safe and Ensures Remarkable Chronic GvHD/Leukemia Free Survival in High-Risk Leukemia Patients
1946 - Novel Tissue-Specific Targeted Radiation Delivery Reduces GI Injury and T Cell Trafficking Attenuating Allogeneic Immune Attack to Reduce GvHD in a Murine BMT Model
1946 - Novel Tissue-Specific Targeted Radiation Delivery Reduces GI Injury and T Cell Trafficking Attenuating Allogeneic Immune Attack to Reduce GvHD in a Murine BMT Model
Ariza McNaughton, L.
Ariza-Heredia, E. J.
Arkam, Y.
Arkenau, H. T.
Arkin, S.
1071 - Progress: Responsiveness Validation of an Electronic Patient Reported Outcome (ePRO) in Adults with Sickle Cell Disease (NCT05407805)
3461 - Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α
3461 - Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α
Arlet, J. B.
Arletti, L.
Arm-Vernez, I.
Armand, P.
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
2865 - Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
2865 - Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
Armand, P.
490 - A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Armand, P.
344 - Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Armand-Ugon, M.
Armant, M.
409 - Regulated Expression of GATA1 As a Gene Therapy Cure for Diamond-Blackfan Anemia
3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
4786 - Therapeutic Gene Editing of HSCs Ex Vivo without in Vitro Culture Avoids Genotoxicity, Simplifies Procedures, and Preserves Efficiency and Stemness
3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
4786 - Therapeutic Gene Editing of HSCs Ex Vivo without in Vitro Culture Avoids Genotoxicity, Simplifies Procedures, and Preserves Efficiency and Stemness
Armari, S.
Armenian, S. H.
119 - Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma
275 - Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid Leukemia
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
4239 - Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
4933 - A Comparison of Financial Hardship Among Survivors of Childhood Cancer Treated with and without Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study
275 - Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid Leukemia
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
4239 - Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
4933 - A Comparison of Financial Hardship Among Survivors of Childhood Cancer Treated with and without Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study
Armes, H.
Armiento, D.
Armijo, G. K.
Armistead, P. M.
270 - Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
3285 - Development of a mRNA Lipid Nanoparticle (mRNA-LNP) Cancer Vaccine to Prevent Leukemia Relapse after Stem Cell Transplant
3312 - Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)—Clinical and Pharmacodynamic Correlates
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
3285 - Development of a mRNA Lipid Nanoparticle (mRNA-LNP) Cancer Vaccine to Prevent Leukemia Relapse after Stem Cell Transplant
3312 - Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)—Clinical and Pharmacodynamic Correlates
Armitage, A. E.
Armitage, J. O.
Armitage, J.
Armour, M.
Armstrong, G. T.
Armstrong, K.
Armstrong, M.
Armstrong, S. A.
43 - Epigenetic Resistance to Menin-MLL1 Inhibition Is Driven By Loss of the Non-Canonical Polycomb Repressive Complex 1.1 in NUP98-Rearranged AML
122 - Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia
1271 - UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability
2588 - Mutant NPM1 Is Recruited to MLL Target Genes Via Its Acidic Stretch and Nuclear Export Factor CRM1 and Regulates Oncogenic Transcription in Acute Myeloid Leukemia
2770 - The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax
122 - Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia
1271 - UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability
2588 - Mutant NPM1 Is Recruited to MLL Target Genes Via Its Acidic Stretch and Nuclear Export Factor CRM1 and Regulates Oncogenic Transcription in Acute Myeloid Leukemia
2770 - The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax
Armuzzi, S.
Arnan Sangerman, M.
853 - Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
1772 - ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder
4065 - Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience
1772 - ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder
4065 - Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience
Arnao, M.
Arnason, J. E.
344 - Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
655 - Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
2295 - G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy
4935 - Clonal Myeloid Disorders Following CAR T-Cell Therapy
655 - Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
2295 - G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy
4935 - Clonal Myeloid Disorders Following CAR T-Cell Therapy
Arnette, D.
Arnhold, V.
Arnold, C.
218 - FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
3025 - Real-World Experience of Asciminib: Factors Associated with Response
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
3025 - Real-World Experience of Asciminib: Factors Associated with Response
Arnold, D.
Arnold, D. M.
Arnold, K. D.
Arnold, L.
Arnold, O.
Arnold, S. D.
579 - Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study
582 - Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia
582 - Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia
Arnone, M.
Arnoux, I.
Arnroth, C.
Arnulf, B.
159 - Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
472 - Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
4514 - Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study
472 - Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
4514 - Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study
Aroldi, A.
Aronova, M.
Aronovich, E.
Arons, E.
Aronson, E.
Aronson, J. H.
Arora, S.
Arora, S.
250 - Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3218 - A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3218 - A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
Arpinati, M.
Arrais Maia, A. C.
Arrais-Rodrigues, C.
Arrate, M. P.
Arrate, M. P.
Arregui, L.
Arriaga-Gomez, E.
Arribas, A.
Arribas, A. J.
Arribas, M.
1821 - Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
3214 - Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
3214 - Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic
Arribas-Layton, M.
Arriola-Martinez, L.
Arroyo, A.
Arroyo, M.
Arru, L. B.
Arruda, A.
47 - Simultaneous Inhibition of SIRT3 and Cholesterol Homeostasis Targets AML Stem Cells By Perturbing Fatty Acid β-Oxidation and Inducing Lipotoxicity
1289 - Intracellular IL-23 Receptor (IL-23R) Is Necessary for AML Viability and Regulates Mitotic Spindle and Centrosome Formation
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
4109 - The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
1289 - Intracellular IL-23 Receptor (IL-23R) Is Necessary for AML Viability and Regulates Mitotic Spindle and Centrosome Formation
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
4109 - The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
Arruda, M. D. G. B.
Arruda, V. R.
Arsalan, A.
Arslan, M. N.
Arslan, O.
Arslan, S.
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
Arslan, S.
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
Arthur, B.
Arthur, B.
Arthur, C. M.
Arthur, C. M.
Arthur, N.
Arthurs, S.
Artico, L.
Arts, P.
Artyomov, M.
Artz, A. S.
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
Arul Rayan, N.
Arulanandam, A.
Arulogun, S. O.
Arun Kumar, S.
Arun, S.
Arvanitakis, A.
Aryal, A.
Aryal, S.
Aryee, M. J.
Asada, N.
54 - Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study
1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
4579 - Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
4579 - Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
Asada, S.
Asagoe, K.
1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
Asakrah, S. K.
Asakura, H.
Asara, J.
Asare, E. V.
Ascensao, J. L.
Asch, A. S.
78 - Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)
1618 - Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
4953 - Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology
1618 - Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
4953 - Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology
Ascha, M. S.
Aschmoneit, N.
Asensi, P.
Asfund, S.
Asghar, N.
Ashby, J. F.
Ashby, T. C.
Ashcraft, E.
Asherman, L.
Ashley, N.
Ashok, D.
Ashok Kumar, P.
Ashouri, K.
Ashraf, B.
Ashrani, A. A.
1123 - The Lupus Anticoagulant Titer Is Associated with Elevated Anti-Phosphatidyl-Serine/Prothrombin Antibody Levels
2334 - Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia
3834 - No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
2334 - Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia
3834 - No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
Ashtiani, M.
Ashton, J. M.
Asija, S.
Asimakopoulos, F.
Askar, F.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Askari, E.
104 - Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy
1194 - Machine Learning Model Defines Higher Risk of Venous Thromboembolism in Young Adults with Multiple Myeloma
1524 - Clonal Architecture and Evolution of Waldenström’s Macroglobulinemia at the Single Cell Level
1194 - Machine Learning Model Defines Higher Risk of Venous Thromboembolism in Young Adults with Multiple Myeloma
1524 - Clonal Architecture and Evolution of Waldenström’s Macroglobulinemia at the Single Cell Level
Askari, E.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
Aslam, M.
117 - Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
Aslan, B.
Aslan, C.
Aslan, J. E.
Aslanis, V.
Asmann, Y.
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
Asmus, E. J.
757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
Asnafi, V.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
2619 - Metabolic Plasticity Reveals a Targetable Vulnerability in Leukemia
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
2619 - Metabolic Plasticity Reveals a Targetable Vulnerability in Leukemia
Asnagli, H.
Asomaning, N.
Asoori, S.
Aspelund, T.
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Asquith, N.
Asres, G.
Assad, A.
236 - Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
Assal, A.
Assanelli, A. A.
Assanto, G. M.
Assatova, B.
Assenmacher, M.
Assmann, J.
Assouline, S.
610 - Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
1630 - Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
- BITEs, immune checkpoint molecules, macrophage checkpoint molecules for AML and high grade MDS-
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
1630 - Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
- BITEs, immune checkpoint molecules, macrophage checkpoint molecules for AML and high grade MDS-
Astbury, C.
Aster, J. C.
Astibia Mahillo, B.
Astle, W.
Astudillo, G. E.
Ataga, K. I.
1055 - Machine Learning Predicts Acute Kidney Injury in Hospitalized Patients with Sickle Cell Disease
1062 - Evaluating Equations for Estimated Glomerular Filtration Rate (eGFR) in Patients with Sickle Cell Disease (SCD)
2239 - Age-related Impact of the CDC’s 2016 Guideline for Prescribing Opioids for Chronic Pain on Opioid Prescribing Levels and Health Outcomes among the Patients with Sickle Cell Disease
1062 - Evaluating Equations for Estimated Glomerular Filtration Rate (eGFR) in Patients with Sickle Cell Disease (SCD)
2239 - Age-related Impact of the CDC’s 2016 Guideline for Prescribing Opioids for Chronic Pain on Opioid Prescribing Levels and Health Outcomes among the Patients with Sickle Cell Disease
Atagozli, T.
Ataide, R.
Atala, A.
Atalar, S.
Atale, N.
Atallah, E. L.
65 - Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
599 - Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia
2689 - Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems
2699 - Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
3011 - Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
3020 - ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
4951 - Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)
- Clinical Discussant on Newly Diagnosed Acute Myeloid Leukemia
- Panel Discussion
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
599 - Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia
2689 - Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems
2699 - Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
3011 - Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
3020 - ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
4951 - Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)
- Clinical Discussant on Newly Diagnosed Acute Myeloid Leukemia
- Panel Discussion
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Atam, S.
Atanackovic, D.
Atanasio, A.
Atanazio, M. J.
Atari, N.
Atenafu, E. G.
1372 - Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up
2127 - Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
2691 - Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
3017 - Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib
3395 - ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies
4011 - Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis
4037 - Clinical Outcomes in De Novo Versus Secondary NPM1-Mutated AML
4370 - Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor
4512 - Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up
2127 - Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
2691 - Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
3017 - Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib
3395 - ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies
4011 - Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis
4037 - Clinical Outcomes in De Novo Versus Secondary NPM1-Mutated AML
4370 - Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor
4512 - Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Ates, G.
Athale, U. H.
2693 - Universal Premedication for Pegylated (PEG)-Asparaginase Treatment in Children with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LLy) Has No Impact on Frequency of Hypersensitivity Reactions
2695 - Impact of Thrombotic Events Occurring during Active Treatment of Leukemia on the Overall Survival and Event-Free Survival: A Systematic Review
2695 - Impact of Thrombotic Events Occurring during Active Treatment of Leukemia on the Overall Survival and Event-Free Survival: A Systematic Review
Athena-Estrada, C.
Atkins, J.
Atkins, J.
Atkinson, A.
Atkinson, A.
Atkinson, J.
Atkinson, S.
Atkinson, S. H.
Atlasi, Y.
Atluri, H.
773 - Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
3000 - A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
3000 - A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA
Atodaria, K.
3616 - Outcomes Among Hospitalized Multiple Myeloma Patients with Chronic Kidney Disease That Received Autologous Stem Cell Transplant: A Nationwide Analysis
3698 - Comparison of Strokes in Adult Hospitalized Patients with Sickle Cell Disease and Patients without Sickle Cell Disease: A Nationwide Analysis
3698 - Comparison of Strokes in Adult Hospitalized Patients with Sickle Cell Disease and Patients without Sickle Cell Disease: A Nationwide Analysis
Atrash, S.
252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
Atrash, S.
565 - Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
Atsriku, C.
Atsuta, Y.
85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies
368 - Indirectly Recognizable Epitopes Derived from Recipient Mismatched HLA-B Are Associated with Adverse Prognosis in Single-Unit Cord Blood Transplantation
876 - The Novel Scoring System to Personalize the Conditioning Intensity in Elderly Patients
990 - Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
2054 - International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
368 - Indirectly Recognizable Epitopes Derived from Recipient Mismatched HLA-B Are Associated with Adverse Prognosis in Single-Unit Cord Blood Transplantation
876 - The Novel Scoring System to Personalize the Conditioning Intensity in Elderly Patients
990 - Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
2054 - International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
Attar, E. C.
Attar, R. M.
Attarbaschi, A.
1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2964 - Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL – First Data from the Austrian CAR-T Network
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2964 - Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL – First Data from the Austrian CAR-T Network
Attardi, E.
Attia, I. Z.
3217 - Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
3817 - Development of a Machine Learning Model Using Electrocardiogram Signals to Determine Acute Pulmonary Embolism
3817 - Development of a Machine Learning Model Using Electrocardiogram Signals to Determine Acute Pulmonary Embolism
Attolico, I.
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
4326 - Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study
4326 - Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study
Attucks, O. C.
Atwater, S.
Au Yeung, K. H. R.
Au-Yeung, R. K.
Aubareda, A.
Auberle, C.
Aubert, G.
Aubert, L.
Aubrey, M. T.
2120 - Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype
3444 - HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)
3444 - HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)
Auclair, D.
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
Audas, T. E.
Audemard, E.
Audet, J.
Audia, S.
23 - Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
Audisio, E.
535 - 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
4071 - A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure
710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
4071 - A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure
Auer, F.
Auer, P.
Auerbach, M.
Augi, T.
Augsberger, C.
Augsburg, C.
August, A.
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
2690 - Desensitization to Pegaspargase in Children with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Is Safe and Does Not Require Intensive Care – a Single Center Experience
2690 - Desensitization to Pegaspargase in Children with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Is Safe and Does Not Require Intensive Care – a Single Center Experience
August, K. J.
2690 - Desensitization to Pegaspargase in Children with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Is Safe and Does Not Require Intensive Care – a Single Center Experience
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4009 - Premedication and Therapeutic Drug Monitoring (TDM) for Pegaspargase: A Prospective Multicenter Multi-Ethnic Study of Pediatric and Adolescent Patients
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4009 - Premedication and Therapeutic Drug Monitoring (TDM) for Pegaspargase: A Prospective Multicenter Multi-Ethnic Study of Pediatric and Adolescent Patients
Aujay, M. A.
Auletta, J.
Auletta, J.
367 - Ongoing Risk of Unrelated Donors Testing Positive for COVID-19 Following Medical Clearance and Impact on Operations: A Report from the National Marrow Donor Program
3379 - Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
3414 - Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
3421 - Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
3379 - Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
3414 - Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
3421 - Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
Aung, F. M.
Auquier, P.
Aurand, L.
3651 - A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria
3652 - A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab
4873 - Patient-Reported Outcomes from a Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria
3652 - A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab
4873 - Patient-Reported Outcomes from a Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria
Aurora, T. D.
Aurran Schleinitz, T.
Aurran-Schleinitz, T.
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
Aurran-Schleinitz, T.
Aurrand-Lions, M.
Aust, D.
Austin, M. J.
Austin, R.
Austin, R.
Auteri, G.
Autio, M.
548 - Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas
1550 - The Composition, Cell Interaction Patterns and Prognostic Impact of the Tumor Microenvironment in Germinal Center B-Cell and Activated B-Cell-like Diffuse Large B-Cell Lymphoma
1552 - Tumor Microenvironment and It’s Prognostic Value Is Different in Testicular and Systemic Diffuse Large B-Cell Lymphoma
1550 - The Composition, Cell Interaction Patterns and Prognostic Impact of the Tumor Microenvironment in Germinal Center B-Cell and Activated B-Cell-like Diffuse Large B-Cell Lymphoma
1552 - Tumor Microenvironment and It’s Prognostic Value Is Different in Testicular and Systemic Diffuse Large B-Cell Lymphoma
Autore, F.
Autran, B.
Avalos, B. R.
2402 - Heterodimerization of CSF3R Splice Variants and Mutants Alter Receptor Function
4727 - Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study
4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
4727 - Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study
4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
Avalos-Reyes, E.
Avanaki, A.
Avelar-Barragan, J.
Avenarius, M. R.
Avenoso, D.
Averbuch, D.
2034 - Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party
4682 - Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic – a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT
4682 - Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic – a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT
Aversa, F.
Avery, J.
Avet Loiseau, H.
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
3714 - Parasympathetic System Impairment Is Associated with Cerebral Microangiopathy in Adults with Sickle Cell Disease
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
3714 - Parasympathetic System Impairment Is Associated with Cerebral Microangiopathy in Adults with Sickle Cell Disease
Avet-Loiseau, H.
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
639 - Intergenic Non-Switch Immunoglobulin Translocations Are Frequently Observed in Genomically Unstable MM
648 - Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification
1902 - In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3139 - Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma
639 - Intergenic Non-Switch Immunoglobulin Translocations Are Frequently Observed in Genomically Unstable MM
648 - Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification
1902 - In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3139 - Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma
Avet-Loiseau, H.
Avetisyan, G.
2177 - Pilot Inter-Laboratory Comparison Study of Optical Genome Mapping Analysis for Cytogenomic Characterization of Hematological Malignancies: A Spanish Multicentric Study
2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
Avezbakiyev, B.
Avigan, D.
261 - Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2295 - G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy
3313 - Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2295 - G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy
3313 - Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
Avigan, Z. M.
Avigdor, A.
263 - Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy
316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment
731 - Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
1400 - The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival
2526 - Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
4444 - Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment
731 - Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
1400 - The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival
2526 - Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
4444 - Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
Ávila, A. I.
Avila, A. M.
Aviv, A.
Aviv, A.
Avivi, I.
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
1928 - Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
4552 - A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
4736 - Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes – a Single Center Longitudinal Cohort Analysis
4771 - Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis
1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
1928 - Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
4552 - A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
4736 - Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes – a Single Center Longitudinal Cohort Analysis
4771 - Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis
Avni, B.
652 - Chronic Graft Versus Host Disease Detected By Tissue-Specific Cell-Free DNA Methylation Biomarkers
2119 - Tecam (Thiotepa, Etoposide, cyclophosphamide, Cytarabine and Melphalan) Is an Effective and Safe Conditioning Regimen for Autologous Transplant in Lymphoma
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
2119 - Tecam (Thiotepa, Etoposide, cyclophosphamide, Cytarabine and Melphalan) Is an Effective and Safe Conditioning Regimen for Autologous Transplant in Lymphoma
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
Avni, B.
Avrahami, G.
Avramis, E.
Avsharian, L.
Awad, S. A.
Awada, A.
2813 - Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1
4104 - RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group
4104 - RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group
Awada, H.
120 - Chip–Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
1605 - Epidemiology, Survival and Second Primary Malignancies in T-Cell Large Granular Lymphocytic Leukemia
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2496 - Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
4061 - MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
1605 - Epidemiology, Survival and Second Primary Malignancies in T-Cell Large Granular Lymphocytic Leukemia
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2496 - Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
4061 - MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis
Awada, H.
Awada, H.
Awada, H.
120 - Chip–Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
2567 - Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3062 - Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association
3064 - Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia
3211 - Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
3227 - Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients
3818 - Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs
3883 - Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
4748 - Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4762 - Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
2567 - Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3062 - Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association
3064 - Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia
3211 - Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
3227 - Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients
3818 - Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs
3883 - Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
4748 - Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4762 - Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M
Awan, F. T.
78 - Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
3114 - Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
3123 - Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4434 - Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
3114 - Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
3123 - Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4434 - Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
Awan-Toor, S.
Awaya, N.
Awoniyi, O.
Awuah, A.
Awwad, M. H.
Ay, C.
519 - Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
521 - Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer
3779 - Repeated Testing Unfolds the Challenge of Diagnosing Von Willebrand Disease: Longitudinal Data from the Vienna Bleeding Biobank
521 - Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer
3779 - Repeated Testing Unfolds the Challenge of Diagnosing Von Willebrand Disease: Longitudinal Data from the Vienna Bleeding Biobank
Ayad, A. A.
Ayala Aguillón, F.
Ayala, A.
Ayala, E.
2923 - Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma
4564 - Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
4770 - Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma
4564 - Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
4770 - Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma
Ayala, I.
Ayala, R.
Ayala, R.
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
1526 - Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy
1882 - Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
3831 - Hip Replacement Surgery and Anticoagulation; A Mortality, Transfusion Need and Venous Thromboembolism Rate Analysis with Trinetx
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
4818 - The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
1526 - Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy
1882 - Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
3831 - Hip Replacement Surgery and Anticoagulation; A Mortality, Transfusion Need and Venous Thromboembolism Rate Analysis with Trinetx
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
4818 - The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates
Ayala, R.
Ayas, M.
266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
Ayash, L.
Ayaz, A.
Aydin, M.
1426 - Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study
4700 - Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning
4700 - Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning
Aydogan, M.
Ayello, J.
Ayers, A.
617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
3544 - Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
3544 - Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
Ayers, E. C.
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
Ayers, L. W.
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Aygun, B.
11 - Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study
886 - Assessing Multi-Level Barriers to Medication Adherence in Youth with Sickle Cell Disease Using Pharmacy-Based Prescription Refill Data
886 - Assessing Multi-Level Barriers to Medication Adherence in Youth with Sickle Cell Disease Using Pharmacy-Based Prescription Refill Data
Aykas, F.
Ayombil, F.
Ayoub, E.
199 - C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas
2610 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
2788 - Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
2812 - Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations
3956 - Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia
2610 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
2788 - Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
2812 - Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations
3956 - Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia
Aypar, U.
Ayres, M.
Ayrons, K.
Ayuk, F. A.
2002 - Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
3222 - Impact of High-Risk Disease on Outcome after CAR-T Cell Therapy for Multiple Myeloma: A Meta-Analysis of 759 Patients
3352 - Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies
3415 - Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation
4665 - Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
3222 - Impact of High-Risk Disease on Outcome after CAR-T Cell Therapy for Multiple Myeloma: A Meta-Analysis of 759 Patients
3352 - Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies
3415 - Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation
4665 - Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
Ayuk, F. A.
Ayyadevara, V. S. S. A.
Ayyappan, S.
444 - Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
Azadniv, M.
Azam, M.
Azeh, I. T.
Azenkot, T.
Azenkot, T.
Azer, S.
Azevedo, J. T.
Azevedo, R. I.
Azhar, M.
Azhar, M.
Azhwar, R.
Azibeiro Melchor, R.
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
Azimi, V.
Azizi, E.
Azmi, A. S.
Azoulay, E.
Azoulay, L. D.
Azoulay, T.
Azouzi, S.
Azzi, G.